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Abstract 
Human African Trypanosomiasis (HAT) is a neglected tropical disease that 
mainly affects the poorest people in sub Saharan Africa. HAT is caused by two 
subspecies of Trypanosoma brucei; T. b. rhodesiense is found in Eastern Africa and 
causes the acute form of the disease, while T. b. gambiense is found in Western 
Africa and causes the chronic form of the disease. With no reliable diagnostic 
screening test, available drugs being rather toxic, and emerging cases of drug 
resistant strains, research on the molecular aspects of the trypanosome is being 
carried out with the hope of identifying potential drug targets and diagnostic markers. 
Since most studies are carried out on cultured blood stream trypanosomes, the 
extent to which these parasites are representative of a real human infection is not 
known. Therefore the aim of this study was to analyze the transcriptome of clinical 
isolates of T. b. rhodesiense from patient peripheral blood and cerebral spinal fluid by 
high throughput sequencing. But given the low parasitaemia during active infection, I 
developed a splice leader priming based Polymerase chain reaction method to 
specifically amplify nanogram amounts of trypanosome total RNA in microgram 
amounts of Human cellular RNA, to an amount sufficient for sequencing.  
The amplification method resulted in trypanosome transcripts covering 60% 
of the T. brucei 6772 unique genes, and with an expression threshold of 5 Rpkm. 
The sequenced amplified libraries (four replicates) were highly reproducible and 
comparable to unamplified libraries generated in the same way. However a 
comparison to the conventional RNASeq generated library showed distortions in the 
transcriptome, which could be corrected for and used to analyze clinical samples. An 
analysis of methods used to purify trypanosomes from blood showed that; even 
though DEAE chromatography and reticulocyte lysis resulted in 10 times more 
parasites than those in the buffy coat isolation method, reticulocyte lysis resulted in 
distortion of the transcriptome. However the DEAE chromatography trypanosomes 
transcriptome which was more comparable to the buffy coat, was not highly 
reproducible. The analysis of genomes from the trypanosomes isolated from the 
patients showed a level of heterogeneity between the samples with significant gene 
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Zusammenfassung 
Die humane afrikanische Trypanosomiasis (HAT) ist eine vernachlässigte 
Krankheit die hauptsächlich die ärmsten Leute in den subsaharischen Ländern 
Afrikas betrifft. HAT wird von zwei Unterarten von Trypanosoma brucei verursacht; T. 
b. rhodesiense  kommt in Ostafrika vor und verursacht die akute Form der Krankheit, 
während T. b. gambiense in Westafrika vorkommt und die chronische Form der 
Krankheit verursacht.  Da es keine verläßlichen diagnostischen Auslesetests gibt, die 
vorhandenen Medikamente ziemlich giftig sind und es neue Fälle von 
arzneimittelresistenten Stämmen gibt wird die Forschung der molekularen Aspekte 
der Trypanosome in der Hoffnung ausgeführt, neue Zielmoleküle und diagnostische 
Marker zu identifizieren. Da die meisten Studien mit kultivierten 
Blutstromtrypanosomen durchgeführt werden, ist nicht bekannt, in welchem Umfang 
diese Parasiten eine reale humane Infektion widerspiegeln. Daher ist das Ziel dieser 
Studie das Transkriptom von klinischen Isolaten aus dem peripheren Blut und der 
Zerebrospinalflüssigkeit von Patienten durch Hochdurchsatzsequenzierung zu 
analysieren. Aufgrund der niedrigen Parasitämie während einer aktiven Infektion 
habe ich eine PCR Methode entwickelt, die einen Primer für den „splice leader“ 
verwendet, um spezifisch trypanosomiale Gesamt-RNA im Nanogrammbereich aus 
Microgrammmengen humaner zellulärer RNA zu amplifizieren, um eine zur 
Sequenzierung ausreichende Menge zu erhalten.  
Die Amplifizierungsmethode führte zu Trypanosomentranskripten, die 60% 
der 6772 einzigartigen T. brucei  Gene abdecken, bei einer Expressionsschwelle von 
5 Rpkm. Die sequenzierten amplifizierten Genbibliotheken (vier Replikate)  waren 
sehr reproduzierbar und vergleichbar mit nicht-amplifizieren Bibliotheken, die auf 
dieselbe Weise hergestellt wurden. Aber ein Vergleich mit konventionellen RNASeq 
Ergebnissen zeigte Verzerrungen im Transkriptom, welche korrigiert werden konnten 
und für die Analyse von klinischen Proben verwendet werden konnten.  Eine Analyse 
der Methoden für die Isolation von Trypanosomen aus Blut zeigte, dass - obwohl 
durch DEAE Chromatographie und Retikulozytenlyse zehnmal mehr Parasiten 
isoliert werden können als mit der Leukozytenfilmisolationsmethode - die 
Retikulozytenlyse  zu einer Verzerrung des Transkriptoms führt. Das DEAE 
Chromatographie Trypanosomentranskriptom jedoch, welches eher mit dem 
Leukozytenfilm-transkriptom vergleichbar war, war nicht sehr reproduzierbar. Die 
Analyse der Genome der Trypanosomen, welche von den Patienten isoliert wurden, 
zeigte ein hohes Ausmaß an Heterogenität zwischen den Proben mit signifikanten 
Variationen der Genkopien, welche hauptsächlich bei den mehrfach kopierten Genen 
beobachtet wurden.  
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1.1 Human African Trypanosomiasis (HAT)  
African trypanosomes are unicellular flagellated parasites, belonging to the 
genus Trypanosoma, family Trypanosomatidae and order Kinetoplastida (Stevens 
and Brisse, 2004). They are called Kinetoplastids due to their peculiar mitochondrial 
DNA known as kinetoplast DNA (kDNA); which is unique in its structure, function, 
mode of replication and is visible by Giemsa staining (Liu et al., 2005; Renger and 
Wolstenholme, 1971; Shapiro and Englund, 1995; Simpson, 1973).  
African trypanosomiasis is caused by three subspecies of Trypanosoma 
brucei, T. b. brucei, T. b. gambiense and T. b. rhodesiense. These parasites are 
transmitted by tsetse flies of the genus Glossina that infest vast areas of sub 
Saharan Africa (Krafsur, 2009). T. b. brucei infects wild and domestic animals 
causing Nagana in live stock (Connor, 1994). It is not pathogenic to humans and this 
is mainly due to presence of the trypanolytic factor (TLF) in normal human plasma, 
which kills the parasite. However T. b. gambiense and T. b. rhodesiense are resistant 
to this trypanolytic factor (Vanhamme and Pays, 2004). There are two types of TLFs; 
TLF-1, which is a high-density lipoprotein particle, (Rifkin, 1978) and TLF-2, which is 
a serum protein binding complex (Raper et al., 1999). Both of these TLFs contain 
haptoglobin related protein, HPR, and apolipoprotein LI, APOL1 (Pays et al., 2006; 
Vanhollebeke and Pays, 2010). T. b. rhodesiense encodes the serum resistance 
associated protein (SRA), which binds TLF-1 making it resistant to lysis (De Greef 
and Hamers, 1994; Xong et al., 1998). On the other hand, T. b. gambiense has no 
SRA gene and is resistant to TLFs by a mechanism that involves the T. b. 
gambiense specific glycoprotein (TgsGP) (Berberof et al., 2001), which prevents the 
trypanosome killing effects of APOL1 (Capewell et al., 2011; Kieft et al., 2012; 
Uzureau et al., 2013). This resistance of T. b. rhodesiense and T. b. gambiense to 
lysis by the trypanolytic factor culminates in human pathology resulting in the 
disease, Sleeping sickness. 
1.1.1 Epidemiology of HAT  
Human African Trypanosomiasis (HAT), also known as Sleeping sickness, is 
caused by two sub-species of T. brucei; T. b. gambiense causes a chronic form of 
the disease in Western and Central Africa and is transmitted to humans by the 
Glossina palpalis or G. fuscipes tsetse flies; while T. b. rhodesiense is responsible for 
the more acute form of the disease in Eastern and Southern Africa and is transmitted 
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by the Glossina moritans or G. fuscipes groups, Fig 1.1 (Brun et al., 2010; Simarro et 
al., 2010). However, Uganda remains the only country with active foci of both 
Gambian and Rhodesian sleeping sickness (Welburn and Odiit, 2002). It also 
represents a region of potential overlap, with fears that the two disease foci could 
eventually merge (Picozzi et al., 2005).  Interestingly, a few sporadic cases of human 
trypanosomiasis being caused by non human-pathogenic trypanosome species have 
been reported. These species were T. b. brucei (Deborggraeve et al., 2008), T. 
congolense (Truc et al., 1998) and T. evansi (Joshi et al., 2005).  
 
                
Figure 1.1 Map showing the spatial distribution of Human African Trypanosomiasis on African 
continent. Uganda represents the only country with active foci for both Gambian and 
Rhodesian sleeping sickness (Map directly copied from Simarro et al., 2010). 
 
Sleeping sickness mainly affects the poorest people in the rural regions of 
Africa. Despite being a disabling and life threatening fatal disease, it is still one of the 
most neglected (Balasegaram et al., 2008; Simarro et al., 2012a). If incidence alone 
is to be considered, the disease appears to be a minor problem compared to other 
tropical diseases. However, when disability-adjusted life years are calculated, also 
considering its severity (untreated HAT results in 100% mortality), HAT ranks third 
behind malaria and schistosomiasis in sub-Saharan Africa (Cattand, 2001).  
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In spite of the socio-economic unrest that disrupted disease surveillance 
(mainly wars), the prevalence of HAT has changed over the years mainly because of 
control and intervention programs including, early diagnosis, treatment, and vector 
control (Brun et al., 2010; Kuzoe, 1993). The number of people at risk of T. b. 
rhodesiense is not known precisely however in 2006, 486 cases were reported and 
this accounts for 3% of the continental HAT cases (Simarro et al., 2008). The T. b. 
gambiense disease has a much more protracted course than the T. b. rhodesiense 
disease (Brun et al., 2010) and is therefore responsible for more than 95% of HAT 
cases. By 2007 the number of new HAT cases reported in Africa was 10,769 (WHO, 
2012).  
1.1.2 Clinical Presentation of HAT 
T. b. rhodesiense and T. b. gambiense cause a clinically similar disease, the 
major difference between them being their virulence (Dumas et al., 1985). Infection 
progress to disease is usually acute in T. b. rhodesiense with an incubation period of 
about 2-3 weeks (Odiit et al., 1997), whereas, T. b. gambiense infection is usually a 
slower chronic infection with an incubation period of several weeks to months 
(Checchi et al., 2008). Following the bite of a trypanosome-infected tsetse fly, the 
trypanosomes differentiate to the bloodstream stage and spread via the local 
draining lymph node into the vascular system. In some but not all HAT patients, a 
local skin reaction or chancre (local inflammatory response) occurs at the site of 
inoculation (Fairbairn and Godfrey, 1957; Naessens et al., 2003).  
There are two recognized stages in the clinical presentation of HAT, the early 
hemolymphatic stage, and the late encephalitic stage when the parasites cross the 
blood brain barrier and colonize the central nervous system (Despommier et al., 
2005; Kennedy, 2004). However, the transition from the early to the late stage is not 
always distinct in T. b. rhodesiense infections (Atouguia and Kennedy, 2000). The 
onset of the early (hemolymphatic) stage is variable but usually occurs 1–3 weeks 
after the bite, with episodes of intermittent fever lasting 1–7 days. During this period 
the parasites proliferate within the blood and lymphatic system and the leading early 
signs and symptoms of this first stage are; chronic and intermittent fever, headache, 
pruritus (itchy rash), arthralgia (joint pains), generalized weakness, and weight loss 
(Apted, 1970). Multiple organs including the spleen, liver, skin, cardiovascular 
system, endocrine system, and eyes may then be infected; and this involvement 
usually underlies the wide spectrum of systemic dysfunction that may occur 
(Atouguia and Kennedy, 2000; Duggan and Hutchinson, 1966).  
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The late (encephalitic) stage of the disease begins after weeks in T. b. rhodesiense 
infection and months in T. b. gambiense infection. This is when the trypanosomes 
cross the blood-brain barrier and invade the central nervous system (Greenwood and 
Whittle, 1980; Masocha et al., 2004; Mulenga et al., 2001). This stage results in a 
chronic encephalopathy, which is associated with headache and mental changes. 
These neurologic features can be grouped into general categories such as 
psychiatric, motor and sensory abnormalities, and sleep disturbances (Atouguia and 
Kennedy, 2000; Duggan and Hutchinson, 1966). If left untreated at this point, the 
disease progresses with severe body wasting to coma and eventually leads to death. 
1.1.3 Diagnosis of HAT 
T. b. rhodesiense and T. b. gambiense parasites are morphologically 
inseparable but they can be distinguished genetically. The human serum resistance-
associated (SRA) gene defines T. b. rhodesiense (Gibson et al., 2002; Njiru et al., 
2004) whereas a receptor-like flagella pocket glycoprotein (TgsGP) is specific to T. b. 
gambiense (Berberof et al., 2001). African trypanosomes are extra cellular parasites 
that live in blood, lymph and can also cross the blood brain barrier into the cerebral 
spinal fluid. Therefore for the diagnosis of trypanosomal infections in humans, it is 
often essential to demonstrate trypanosomes in lymph node aspirate, blood, or 
cerebrospinal fluid. In this respect, HAT diagnosis follows a three-step procedure 
which involves screening, diagnostic confirmation and staging of the disease 
(Chappuis et al., 2005).  
In T. b. gambiense endemic areas, the Card Agglutination Test for 
Trypanosomiasis (CATT) is a rapid serological test that is used in mass screening 
(Magnus et al., 1978b). It is based on an agglutination assay consisting of lyophilized 
bloodstream form T. b. gambiense expressing the variable antigen type LiTat 1.3, 
which detects specific antibodies in blood, plasma or serum of patients. The reported 
sensitivity of the CATT on undiluted whole blood (CATT-wb) varies from 87 to 98% 
(Noireau et al., 1987; Robays et al., 2004; Truc et al., 2002). However, false-negative 
CATT results have been reported (Penchenier et al., 1991), and this is due to 
patients infected with T. b. gambiense strains that lack or do not express the LiTat 
1.3 gene (Dukes et al., 1992; Enyaru et al., 1998). For such cases, the LATEX 
agglutination test, a field alternative to the CATT that combines three purified 
variable surface antigens (LiTat 1.3, 1.5, and 1.6), was developed (Büscher et al., 
1999; Penchenier et al., 2003). Other highly sensitive serological tests, such as 
immunofluorescence antibody test, IFAT (Magnus et al., 1978a), and enzyme-linked 
immuno sorbent assays, ELISA (Lejon et al., 1998), were developed but their use is 
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limited to reference laboratories and not routine field diagnosis. 
For all HAT patients, there is a need for parasitological confirmation demonstrating 
the presence of trypanosomes in any body fluid or tissue. This is often carried out by 
microscopic examination of chancre aspirate, lymph node aspirate, wet and thick 
blood films, and/or cerebral spinal fluid (Henry et al., 1981; Simarro et al., 2003; Van 
Meirvenne, 1999). But given the low sensitivity of these techniques, concentration 
methods such as the micro-haematocrit centrifugation (Woo, 1970), Quantitative 
buffy coat (Ancelle et al., 1997), miniature anion-exchange centrifugation (Lumsden 
et al., 1979) and fluorescence microscopy with acridine orange staining (Biéler et al., 
2012), were developed. However these procedures are not routinely used in field 
diagnosis because they are time consuming and use sophisticated equipment. Due 
to the absence of sufficiently specific clinical signs and blood tests indicating the 
progress from first to second-stage HAT, staging of patients still relies on 
examination of cerebral spinal fluid (CSF) obtained by lumbar puncture (Kennedy, 
2008). According to the World Health Organization recommendations (WHO, 1998), 
second stage HAT is defined by the presence of trypanosomes and/or >5 white blood 
cells/µL in the CSF or increased protein content (>370mg/L). In addition, a high IgM 
concentration in CSF is considered a reliable marker of neurological involvement 
(Greenwood and Whittle, 1980; Lejon et al., 2002b). This then distinguishes the 
hemolymphatic stage from the encephalitic stage, and is therefore the basis for the 
choice of drug treatment (Rodgers, 2009); since only few trypanocides are able to 
cross the blood brain barrier.   
In T. b. rhodesiense endemic areas, there is no CATT equivalent test and 
therefore field screening relies on clinical signs and symptoms. The diagnostic 
confirmation and staging of T. b. rhodesiense HAT is based on the same methods as 
described for T. b. gambiense disease. However parasitological confirmation of T. b. 
rhodesiense infection is relatively easy because of the high parasiteamia, and so 
most patients are diagnosed by examination of a stained thin or thick blood smear 
(Chappuis et al., 2005; Odiit et al., 1997). The major drawback to parasite detection 
is the fact that sensitivity is quite low; for example, direct microscopy of thick blood 
films has a detection threshold of 5000 trypanosomes per ml of blood. This limit may 
miss the diagnosis in up to 50% of the infections (Chappuis et al., 2005). Hence, a 
number of research efforts have been focused on developing new diagnostic tools 
including; recombinant or native trypanosome antigens that could be used to develop 
an improved serological test (Hutchinson et al., 2004; Manful et al., 2010), methods 
to detect parasite antigens in blood or CSF (Papadopoulos et al., 2004), proteomic 
fingerprinting (Agranoff et al., 2005), loop-mediated isothermal amplification, (Kuboki 
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et al., 2003; Njiru et al., 2008). But recently, an initiative by World Health 
Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) was 
launched to develop methods for diagnosis and staging of HAT. 
1.1.4 Treatment of HAT 
The phenomenon of antigenic variation leaves only a slim hope for a vaccine 
against human African trypanosomiasis (Magez et al., 2010). Disease control also 
relies on vector control by the use of tsetse fly traps, insecticides and sterile insect 
technique (SIT), thus reducing the fly populations. However, these initiatives have 
been difficult to sustain in affected areas and their effectiveness has been 
compromised in the long-run (Aksoy, 2003). With the limitations from this form of 
intervention, chemotherapy offers an effective solution. The current chemotherapy for 
human sleeping sickness is unreliable, with all the main drugs used for early stage 
(Suramin, Pentamidine) and late-stage disease (Melarsoprol, Eflornithine) being 
unavailable orally, with a degree of ineffectiveness and sometimes toxic to the 
patients (Croft et al., 2005; Fairlamb, 2003).  
 
Early stage HAT treatment 
The early-stage T. b. gambiense HAT is treated with pentamidine, which is 
usually administered by the intramuscular route (Pepin and Milord, 1994). Its major 
side effects include, damage to the liver, kidneys and the pancreas, the latter leading 
to diabetes (Fairlamb, 2003). Early stage T. b. rhodesiense HAT is treated with 
intravenous suramin, which is usually effective especially when given the early 
stages of infection, but can result in potential life-threatening side-effects which 
include collapse with nausea, vomiting and shock. Other severe delayed reactions 
may include kidney damage (particularly in malnourished patients), exfoliative 
dermatitis, agranulocytosis, haemolytic anaemia, jaundice and severe diarrhoea, all 
of which can be fatal (Fairlamb, 2003; Fairlamb and Bowman, 1980).  
 
Late stage HAT treatment 
The late stage of HAT, characterized by trypanosomes crossing the blood 
brain barrier into the central nervous system, is more problematic to treat because 
the drugs used in this case are more toxic (Atouguia and Kennedy, 2000; Kennedy, 
2004). The only drug available for treatment of late-stage T. b. rhodesiense HAT is 
melarsoprol. It is an organic arsenical that acts on trypanothione, a trypanosomal 
molecule that maintains an intracellular reducing environment (Fairlamb et al., 1989).  
However, melarsoprol also binds to other sulfhydryl-containing agents in the cell, and 
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its uptake into African trypanosomes has been attributed to the P2 purine nucleoside 
transporter (Carter et al., 1995; Fairlamb and Cerami, 1992). Melarsoprol is 
administered intravenously in propylene glycol because it has a very low solubility in 
water and the injections are extremely painful for the patients (Kennedy, 2012; 
Kuepfer et al., 2012). But even though melarsoprol is usually effective, treatment 
failures due to drug resistance have been reported (Legros et al., 1999). Melarsoprol 
is extremely toxic producing a post-treatment reactive encephalopathy in 10% of 
patients, half of whom die, leading to an overall mortality from treatment of about 5% 
(Kennedy, 2008; Pepin and Milord, 1994). The Late-stage T. b. gambiense HAT is 
currently being treated with nifurtimox–eflornithine combination therapy, NECT 
(Simarro et al., 2012b), although it was previously under monotherapy with 
eflornithine (Burri and Brun, 2003). Interestingly, the mortality from combination 
therapy was reduced to 0.7% (one of 143) as compared to 2.1% (three of 144) for 
eflornithine monotherapy (Priotto et al., 2009). However, eflornithine does have many 
side effects including bone marrow toxicity, alopecia, seizures, and gastrointestinal 
symptoms (Burri and Brun, 2003).  
 
Potential new drugs for treatment of HAT 
All the drugs highlighted above have been in use for over 50 years and they 
are deemed undesirable in terms of administration, toxicity and reported resistance 
(Brun et al., 2010). However the recent development of new compounds that have 
entered clinical trials, offer hope in new drugs to treat HAT (Barrett, 2010; Brun et al., 
2011). For the late stage T. b. gambiense HAT, the nitroheterocyclic drug 
fexinidazole is being tested as an oral treatment for it was found to be both effective 
and non-toxic in animal models of sleeping sickness. It is yet to undergo phase 2 
clinical trials (Kaiser et al., 2011; Torreele et al., 2010). In addition is a new orally 
active compound benzoxaborole, which was able to cure CNS stage trypanosomal 
infections in a murine model, and is now under phase 1 trial (Jacobs et al., 2011a; 
Jacobs et al., 2011b). For the case of T. b. rhodesiense HAT, an improvement has 
been made in the delivery of mode of melarsoprol through melarsoprol-cyclodextrin 
inclusion complexes, making the drug more soluble in water. When administered 
orally, these complexes were shown to be effective in curing CNS trypanosomiasis in 




1.1.5 Immunobiology of HAT 
The understanding of the immunological events that occur in HAT is essential 
in identifying the precise role of inflammatory responses in the pathophysiology of the 
infection. However, various animal models have provided conflicting evidence 
regarding the immunologic factors that influence the magnitude of resistance to 
infection (Namangala et al., 2001). But, as a result of African trypanosome 
adaptation to growth in experimental mouse models, much of the knowledge of the 
biology of these parasites comes from such studies (Sternberg, 2004). The overall 
host response to the disease requires the contribution of VSG-specific B and T cell 
responses (Reinitz and Mansfield, 1990; Schleifer et al., 1993) and the 
macrophage/monocyte phagocyte system (Dempsey and Mansfield, 1983; 
Vincendeau et al., 1999) to resolve the infection. In addition, studies suggest that 
cytokine responses influence the outcome of African trypanosomiasis (Hertz et al., 
1998; Namangala et al., 2000; Uzonna et al., 1999). There are also reported cases of 
asymptomatic carriers and spontaneous cure among T. b. gambiense HAT patients 
(Bucheton et al., 2011; Jamonneau et al., 2012).  
 
Antigenic variation and antibody responses 
The primary immune evasion strategy by African trypanosomes is by 
antigenic variation (Pays et al., 2004; Vanhamme et al., 2001). Trypanosomes are 
covered with a coat of variant surface glycoproteins, VSG, which are 
immunodominant antigens that elicit both T-cell dependent and independent B-cell 
responses, depending on their conformation (Mansfield, 1994). Antibody opsonized 
trypanosomes are effectively cleared presumably by the host’s lymphoreticular 
system (Macaskill et al., 1981). However, the trypanosomes are able to undergo 
antigenic variation due to the genomic presence of a repertoire of more than 1000 
transcriptionally inactive VSG genes under a single active promoter (Pays et al., 
2004), which effects continuous stochastic switching of VSG genes (Taylor and 
Rudenko, 2006). This then enables the trypanosome to maintain a state of chronic 
infection in the host. The humoral response to VSG also has an immune-pathological 
effect whereby, the VSG elicits polyclonal B-cell activation and during human 
infection, results in the generation of auto-antibodies (Kazyumba et al., 1986) and 
immune complex disease (Lambert et al., 1981). Furthermore, during the 
meningoencephalitic stage of infection, trypanosome-specific IgG, IgM and 
polyclonal IgM responses have been detected in the cerebrospinal fluid (Lejon et al., 
1998). These may be derived from modified plasma cells known as Mott or morular 
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cells in the white matter and also plasma cells which form perivascular infiltrates in 
the brain (Kennedy, 2004).  
 
Cytokine activation 
Following the infection by African trypanosomes, the early innate response is 
triggered leading to the release of pro-inflammatory mediators including; cytokines, 
interleukins IL-1, IL-6, IL-12 and tumour necrosis factor alpha (TNF-α) as well as 
nitric oxide (MacLean et al., 2001a; Magez et al., 1997; Tachado and Schofield, 
1994). In a study of T. b. rhodesiense patients in Uganda, both early and late stage 
infections were characterized by elevated levels of IFN-γ, TNF-α and IL-10; although 
IFN-γ levels did diminish in the late-stage cases (MacLean et al., 1999; MacLean et 
al., 2001a). In T. b. gambiense patients, one study demonstrated increased plasma 
IL-10, IL-6 and IL-8, but no detectable IFN-γ or TNF-α (Lejon et al., 2002a). However, 
other studies detected elevated TNF-α levels in T. b. gambiense patients, which 
correlated with the severity of disease (Okomo-Assoumou et al., 1995; Rhind et al., 
1997). The infection-associated production and systemic presence of TNF is possibly 
related to fever induction and to the severity of trypanosomosis induced pathology 
(Magez et al., 2002). It was indeed observed that the inflammation in the brain and 
occurrence of the neurological signs during the late-stage meningoencephalitic 
phase of the infections, were both TNF related (Okomo-Assoumou et al., 1995). In 
addition, the high incidence of mortality following anti-trypanosomosis treatment is 
associated with TNF (Lucas et al., 1993). The early release of these pro-
inflammatory factors enables the early acquired immune responses to the parasite 
variant surface glycoprotein (Magez et al., 2002). The early release of IL-12 
promotes T helper (Th) cells to release cytokines, particularly interferon-gamma 
(IFN-γ), which is responsible for host resistance against parasites spreading 
throughout host tissues (MacLean et al., 2001a). This early resistance is, however, 
superseded by later immune responses that are associated with the spread of 
trypanosomes to the CNS. In this subsequent chronic phase of infection, 
immunosuppression is associated with cytokines, such as IL-10, that down-regulate 





1.2 Gene expression in trypanosomes 
1.2.1 Genome organization and transcription 
The chromatin in the trypanosome nucleus is arranged in nucleosomes for 
which both conserved and divergent histones have been identified (Hecker et al., 
1995). The genomes of T. b. brucei (Berriman et al., 2005) and T. b. gambiense 
(Jackson et al., 2010) have been sequenced and annotated. T. brucei has a diploid 
genome with an estimated haploid DNA content of around 3.5 - 4 x 107 base pairs 
(Berriman et al., 2005). The nuclear genome consists of three chromosome classes, 
megabase, intermediate and mini chromosomes. The mega base chromosomes of 
this diploid genome contain the expressed genes and form at least 11 homologous 
chromosome pairs, Fig 1.2 (Daniels et al., 2010). In addition, strain dependent 
chromosomal length polymorphisms exist for this chromosomal set (El-Sayed et al., 
2000; Ersfeld et al., 1999). The genome of T. brucei contains approximately 9,068 
predicted genes including 900 pseudogenes and 1700 genes that are specific to T. 
brucei (Berriman et al., 2005). In trypanosomes, the majority of protein coding genes 
are organized in polycistronic units that are transcribed by RNA polymerase II 
(Palenchar and Bellofatto, 2006). These polycistronic RNA precursors are then 
processed into mature monocistronic mRNAs by trans-splicing of a 39nt leader 
sequence to the 5’ end and polyadenylation of the 3’ end (Liang et al., 2003). 
However, most genes in the polycistronic unit are not functionally related, and gene 
regulation occurs mainly at the post-transcriptional level operating on mRNA 
processing and mRNA degradation (Clayton and Shapira, 2007). The only known 
exceptions are procyclin and VSG genes, which are regulated at the transcriptional 
level. These genes are transcribed by RNA polymerase I (Gunzl et al., 2003), and 
the transcription rate is thought to be developmentally controlled through epigenetic 
regulation (Figueiredo et al., 2009; Glover and Horn, 2006; Siegel et al., 2009). 
Unfortunately, there is little known about RNA polymerase II promoters in 
trypanosomes, and the only one that is well characterized is the promoter for the 





Figure 1.2  Schematic representation of the T. brucei genome. Chromosomal organization of 
genes according to their class and transcribing polymerase. The colored bars indicate the 
positions and lengths of different genetic elements relative to the chromosome backbone 
(black line). The bars above the lines indicate transcription toward the right; bars below the 
lines indicate transcription toward the left. When a number of a similar elements are present 
in close proximity in the genome, this is indicated by nX next to bar (where n is the number of 
elements). Noncoding RNA genes have been given a minimum bar length to facilitate 
visualization. Only the largest assembled contig is represented for each chromosome. 
Chromosomes 9 to 11 have been split across two lines. (Directly copied from Daniels et al., 
2010). 
1.2.2 Transcriptomic analysis of gene expression  
The transcriptome is the complete set of transcripts (genetic code transcribed 
to RNA molecules) in a cell, for a specific developmental stage or physiological 
condition. It is also defined as the polyadenylated products of RNA polymerase II 
activity (Tang et al., 2010; Wang et al., 2009). Even though within an organism or 
tissue all cells have the same genome, diverse phenotypes exist because of varying 
types and amounts of mRNA transcripts (Kalisky et al., 2011; Tang et al., 2011). 
Therefore transcriptomic analyses (of mRNAs, non coding RNAs and small RNAs), 
enable understanding of the transcriptional structure of genes in terms of their start 
sites, 5′ and 3′ ends, splicing patterns and other post-transcriptional modifications. 
This is in turn relevant in quantifying the changing expression levels of each 
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transcript during development and under different stimuli or environmental conditions 
(Wang et al., 2009).  
By using high throughput microarrays to study the transcriptome of 
trypanosomes, it was observed that between 2 to 10% of all mRNA in trypanosomes 
were developmentally regulated (Jensen et al., 2009; Kabani et al., 2009; Queiroz et 
al., 2009). However, these hybridisation based microarrays do suffer from 
background hybridization, limited accuracy of expression for transcripts in low 
abundance, and cannot be used to detect splice variants or unknown genes (due to 
reliance upon existing knowledge about genome sequence) (Okoniewski and Miller, 
2006; Royce et al., 2007). The drawbacks of microarrays have been circumvented by 
the recent development of high-throughput DNA sequencing platforms such as 
Roche/454 (http://www.454.com), Illumina (http://www.illumina.com), Applied 
Biosystems/Life Technologies (http://www.appliedbiosystems.com), and Helicos 
(http://www.helicosbio.com) (Fu et al., 2009; Marioni et al., 2008; Metzker, 2010). 
These next generation sequencing (NGS) methods have provided a new approach 
for both mapping and quantifying transcriptomes (Mardis, 2008; Ozsolak and Milos, 
2011; Wang et al., 2009).  
An analysis of the transcriptome of Trypanosoma brucei using the next 
generation sequencing platforms revealed a number of dynamic properties of the 
gene expression profile of this parasite (Kolev et al., 2010; Nilsson et al., 2010; 
Siegel et al., 2010; Veitch et al., 2010). For instance, RNA-seq analysis of the trans 
splicing junctions (coverage of the splice leader and 5’ end of the mRNA) enabled 
the 5’ UTR regions for 8,960 transcripts to be mapped. Furthermore, this approach 
was able to identify polyadenylation sites (PAS) for between 2,081 and 5,948 genes 
(Kolev et al., 2010; Siegel et al., 2010). In addition, by using the splice leader 
trapping method (Nilsson et al., 2010), the splice acceptor sites (SAS) for 8,277 
genes in the long slender bloodstream forms were identified. These UTRs are 
important determinants of transcript stability through regulation by cis-acting 
elements (Clayton and Shapira, 2007; Fernández-Moya and Estévez, 2010; 
Ouellette and Papadopoulou, 2009). RNASeq analysis of the global mRNA 
degradation rates in bloodstream form trypanosomes showed that most mRNAs had 
half lives less than 20 min (Manful et al., 2011).  
1.2.3 Transcriptome analysis of nanogram amounts of RNA 
High through put expression analysis has provided new insights into the 
biology of trypanosomes (Siegel et al., 2011). However, these studies required 
relatively large amounts total RNA (typically 10–30 µg of total RNA), which was 
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obtained from in vitro cultured trypanosomes. It is important to extend these 
analytical methods to much smaller quantities of trypanosomes, such as those found 
in infected clinical specimens as well as tsetse flies. But most biological specimens 
(for example blood) directly obtained ex vivo in a clinical setting (mainly for diagnostic 
purposes) don’t often yield enough RNA for high throughput gene expression 
analysis (Marteau et al., 2005; Mitsuhashi et al., 2006). However strategies have 
been developed to amplify low amounts of total RNA (less than 100ng) to an amount 
sufficient for gene profiling analysis (Pan et al., 2013; Tang et al., 2011; Tariq et al., 
2011; Wang, 2005).  
There are two principle methods of amplification of mRNA without skewing 
relative transcript abundance. First is, linear amplification of cDNA by in vitro 
transcription (IVT) using a DNA dependent RNA polymerase (Stirewalt et al., 2004; 
Van Gelder et al., 1990) and secondly, exponential amplification of cDNA by DNA 
polymerase chain reaction, PCR (Brady et al., 1990; Iscove et al., 2002). The 
combination of PCR amplification to generate sufficient ds-cDNA template followed 
by in vitro transcription has also been used to amplify RNA from minimal stating 
material (Klur et al., 2004). These methods have been extensively used to study 
single mammalian cell transcriptomes (Tang et al., 2011). A single mammalian cell 
contains approximately 20 to 40 pg of total RNA of which 0.5 to 1.0 pg is mRNA 
(Roozemond, 1976; Uemura, 1980). For standard microarray analysis, this needs to 
be amplified around ten million–fold (Livesey, 2003). The merit of the PCR strategy is 
the exponential amplification of cDNAs so that single-cell cDNAs can be amplified 
millions-fold in several hours. Its disadvantage is the accumulation of primer dimers 
and other nonspecific byproducts during amplification, especially during later cycles 
of PCR (Brady et al., 1990; Kurimoto et al., 2006; Livesey, 2003). The advantage of 
the IVT strategy is its stringent specificity while reducing accumulation of nonspecific 
byproducts (Eberwine et al., 1992); its disadvantage is that cRNAs typically less than 
1Kb are generated. The IVT procedure is also more tedious and time-consuming, 
and every round of IVT can amplify the cDNAs only up to 1,000-fold (Kawasaki, 
2004; Livesey, 2003). By modifying and improving the amplification PCR strategy by 
(Kurimoto et al., 2007), mRNA-seq on a single cell was carried out and it showed a 
64% coverage of expressed genes (Tang et al., 2010; Tang et al., 2009). In this 
study, the exponential PCR amplification strategy was used to develop a protocol to 
specifically amplify trypanosome RNA in clinical samples. 
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1.3 Aim of the study 
1.3.1 Study objectives 
This study was aimed at analyzing for the differential gene expression of T. b. 
rhodesiense in the peripheral blood and cerebral spinal fluid of Sleeping sickness 
patients.  
The specific objectives involved: 
1. Optimizing a method to analyze the transcriptome of trypanosomes from 
clinical samples. 
2. Analysis of the effect of different methods of isolation of trypanosomes from 
blood on there transcriptomes. 
3. Analysis of transcriptomes of trypanosomes isolated from HAT patient 
peripheral blood and cerebral spinal fluid.  
4. Analysis of structural variations within the genomes of trypanosomes isolated 
from the patients. 
1.3.2 Significance of study 
Most of the expression-profiling studies on African trypanosomes have been 
performed on cultured parasites or high-density mouse infections. The extent to 
which these parasites are representative of a real human infection is still not known. 
Therefore this study was aimed at high throughput sequencing analysis of the 
transcriptome of T. b. rhodesiense obtained from HAT patients. Analysis of the 
differential gene expression of T. b. rhodesiense in the bloodstream and cerebral 
spinal fluid would provide an insight into the human-trypanosome interaction, which 
would thus enable in the identification of possible targets for chemotherapy for the 
safe treatment of early and late stages of Sleeping sickness. 
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2 Materials and Methods 
Parts of this section are derived from a manuscript that has been submitted for 
publication and has therefore been written or modified by other people (Fadda, A and 
Clayton, C.) 
2.1 Clinical sample collection 
2.1.1 Ethical clearance  
The ethical approvals of protocols were obtained from the Ministry of Health, Uganda 
and Ethics committee of University of Heidelberg, Germany. All patients recruited 
into this study received written and verbal information explaining the purpose of the 
study and they gave informed consent. The ethical consent forms were written in 
English and translated into the local languages. For the children and adolescent 
participants (below 18 years), the parents or guardians gave the informed consent on 
their behalf. The patient recruitment was carried out at Lwala hospital in 
Kaberamaido district, which is situated in the T. b. rhodesiense HAT foci of 
Northeastern Uganda. Diagnosis of HAT was carried out by microscopic detection of 
motile trypanosomes on a wet blood smear of finger prick blood. For those 
trypanosome positive cases, staging was carried out by microscopic examination of 
CSF obtained by lumbar puncture. Diagnosis was carried out on admission and on 
discharge as part of the normal clinical follow-up procedure. The clinical officers at 
the out patients department (OPD) carried out the medical examination of all patients 
recruited into the study. An experienced senior nurse or laboratory technician carried 
out the phlebotomy and lumbar puncture procedures. I trained a laboratory 
technologist, James Ochieng, on the sample processing methodology including 
parasite isolation, counting, and storage. He was based at the hospital and carried 
out the sample collection. 
2.1.2 Peripheral blood collection 
Peripheral blood, PB (3-4ml) from confirmed HAT patients, was collected into an 
EDTA tube (BD Vacutainer) upon phlebotomy. An aliquot of the whole blood (600µl) 
was cryopreserved, a drop (10µl) was spotted on Whatman FTA and the remaining 
volume centrifuged at 3000rpm for 10min at room temperature. The plasma was 
aspirated off for storage and the buffy coat layer (approx. 500 µl) transferred to a 
1.5ml eppendoff tube. Drew 10µl onto a nuebaur haemocytometer for a cell count 
(trypanosomes and WBC). The buffy coat volume was then centrifuged at 6000rpm 
for 2min at room temperature and the pellet fraction resuspended in 1ml of Trifast 
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reagent (Peqlab, GmbH), then transferred to cryotube for immediate freezing in liquid 
nitrogen. 
2.1.3 Cerebral spinal fluid collection 
Cerebral spinal fluid, CSF (2-4ml) obtained from confirmed HAT patients by lumbar 
puncture, was centrifuged at 3000rpm for 10min. The supernatant was aspirated off 
leaving approximately 500µl, which was transferred to a 1.5ml eppendoff tube. Then 
drew 10µl for the cell count, and centrifuged the remaining volume at 6000rpm for 
2min at room temperature. The pellet fraction was then resuspended in 1ml Trifast 
(Peqlab, GmbH), transferred to a cryotube and immediately frozen in liquid nitrogen. 
2.1.4 Haemocytometer count  
The total cell count was determined microscopically by drawing 10µl of either buffy 
coat or CSF sample onto a neubauer counting chamber (Fig 2.1) as described 
above. The total numbers of cells (WBCs and Trypanosomes), from the 16-square-
fields were counted, and the average from the 4 big squares (containing the 16 
squares) was multiplied by 1x104; which equated to the cell density in 1ml volume.  
                                    
Figure 2.1 Representation of the counting chamber of the neubauer hemocytometer. 
2.1.5 Speciation PCR on FTA blood 
In order to confirm that all the cases were T. b. rhodesiense infections, PCR was 
carried out on the SRA gene as described (Radwanska et al., 2002). The PCR was 
carried out on DNA extracted from the patient blood spotted on Whatman FTA.  
Briefly, the FTA spots were punched with a sterile 7.9mm diameter disc punch (Ted 
Pella Inc.) into a 1.5ml eppendof tube. The discs were then rinsed in 500µl of distilled 
water by vortexing 3 times for 3 seconds. The water was drawn off and fresh 100 µl 
of water was pipetted into the tubes. This was then incubated at 95°C for 30min. 3µl 
of this was used as a template for PCR amplification of the SRA gene. The DNA 
templates were amplified in 50µl of PCR mixture containing 1X PCR buffer, 1.5 mM 
MgCl2, 100µM of each of the four dNTPs, 1µM of each primer, and 2 units Taq DNA 
polymerase. The nested PCR was carried out using two sets of primers under the 
same conditions. The first primer set (SRA-1_s, 5'-CCTGATAAAACAAGTATCG 
GCAGCAA-3', & SRA-1_as, 5'-CGGTGACCAATTCATCTGCTGCTGTT-3') and the 
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second primer set (SRA-2_s, 5'-ATAGTGACAAGATGCGTACTCAACGC-3' & SRA-
2_as, 5'-AATGTGTTCGAGTACTTCGGTCACGCT-3'). PCR conditions were, 1min at 
98°C, followed by 25 cycles of 55sec at 98°C, 30sec at 64°C, and 2min at 72°C, and 
a final extension of 5min at 72°C. 
2.2 Trypanosome cultures 
2.2.1 In-vivo cultures 
Field isolates of T. b. rhodesiense in cryopreserved blood stabilates were inoculated 
intra-muscularly in rats. The rats were then tail bled on a daily basis to check for 
parasitaemia microscopically. At peak parasitaemia (approximately 4x106 cells/ml), 
the rats were sacrificed and approximately 4ml of blood was drawn by cardiac 
puncture into an EDTA vacutainer for further experimentation. For the in vitro 
cultured T. b. rhodesiense strain Tbr729, approximately 5000 parasites were injected 
in a rat and peak parasitaemia would be observed within 5 days post infection. 
2.2.2 In-vitro cultures 
Bloodstream-form Trypanosoma brucei strains (Tbr729 and Lister 427) were cultured 
in loosely capped flat-bottomed T-flasks in an incubator at 37°C, 5% CO2, in a 
humified atmosphere. The cell densities were maintained between 2-10x105 cells/ml 
in supplemented HMI-9 medium (Table 2.1).  
 
Table 2.1 Trypanosome culture HMI-9 medium 
Reagent Conc. 
aIMDM (Gibco) 17.66g/L 
NaHCO3 (Roth) 36mM 
Hypoxanthine (Serva) 1mM 
Na-pyruvate (Serva) 1mM 
Thymidine (Sigma) 160mM 
Bathocupronsulphonate (Serva) 50mM 
 
Supplemented HMI-9 medium, 500ml 
bHeat-inactivated FCS 10% (v/v) 
Penicillin/Streptomycin (Sigma) 50U/L (5ml) 
L-Cysteine-HCl.H2O 1.5mM  
β-mercaptoethanol (Sigma) 0.14% 
aIscove’s Modified Dulbecco’s Medium, no supplements 
bFCS heat-inactivated by incubation at 56ºC for 30min 
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2.3 Isolation of Trypanosomes from blood 
2.3.1 Anion Exchange chromatography  
Trypanosomes in infected rat blood were harvested by anion exchange on DEAE 
cellulose as described by (Lanham and Godfrey, 1970). Briefly, 20ml packed slurry 
volume of DEAE cellulose resin (Sigma) pre-equilibrated in phosphate saline glucose 
(PSG) buffer, pH 8, was set up in a 30ml syringe. The column was equilibrated with 3 
column volumes of PSG and thereafter loaded with anti-coagulated rat blood at room 
temperature. The trypanosomes were eluted with PSG into a 15ml tube and then 
centrifuged for 10min at 2500rpm. The parasites were then resuspended in Trifast 
reagent for RNA analysis or subjected to genomic DNA extraction using the 
Zymogen kit. 
2.3.2 Hemolysis centrifugation  
Trypanosomes in infected rat blood were also harvested by hemolysis followed by 
centrifugation as described by (Njogu and Kiaira, 1982). Briefly, to one volume of 
infected rat blood was added 3 volumes of Erythrocyte lysis buffer (Qiagen), gently 
mixed and incubated at room temperature for 7min. This was then centrifuged at 
2500rpm for 10min. The pellet was then resuspended in Trifast reagent for 
subsequent RNA extraction. 
2.3.3 Buffy coat   
The infected rat blood in an EDTA tube was centrifuged at 3000 rpm for 10min to 
differentially separate the red blood cells from the white blood cells in the buffy coat. 
The buffy coat, which contains the trypanosomes, was pipetted off and centrifuged at 
6000rpm for 2min. The pellet was then resuspended in Trifast for RNA extraction. 
2.4 Trypanosome Transcriptome Analysis 
2.4.1 Total RNA extraction 
Total RNA from the cellular pellets was extracted using Trifast reagent (Peqlab, 
GmbH). 200µl of chloroform was added to the 1ml cell suspension, vortexed 
vigorously and incubated at room temperature for 3min. The mix was then 
centrifuged at 13000rpm for 10min at 4°C and the aqueous phase pipetted into a 
1.5ml eppendoff lobind tube. 500µl of isopropanol was then added, mixed thoroughly 
and incubated at room temperature for 10min to allow for RNA precipitation. The mix 
was then centrifuged at 13000rpm, 4°C for 20min and the RNA pellet washed with 
1ml of 75% ethanol. The ethanol was removed by centrifugation at 13000rpm for 
5min, the RNA pellet air dried and dissolved in 20µl of nuclease free water. The total 
RNA concentration was then determined using the Qubit 2.0 fluorometer (Invitrogen). 
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2.4.2 PolyA+ selection of mRNA 
RNA molecules with a 3’ end polyA tail (mRNA) were selectively purified from the 
total RNA. For this, the total RNA was resuspended in 500µl of RNA denaturing 
buffer (20mM HEPES, pH7.4, 10mM EDTA, pH7.4, 1% SDS) and incubated at 65°C 
for 10min then on ice for 2min. 750µl of RNA dilution buffer (20mM HEPES, pH7.4, 
800mM NaCl) and 100µl of pretreated oligo(dT) cellulose (Amersham, Table 2.2) 
was then added, and the tube placed on a rotatory mixer for 15min at room 
temperature. The mix was then centrifuged at 12000rpm for 2min and the cellulose 
pellet washed 2 times with RNA washing buffer (20mM HEPES, pH7.4, 5mM EDTA, 
pH7.4, 0.5% SDS), centrifuging each time at 12000rpm for 2min. The cellulose was 
then incubated in 150µl of RNAse free water, mixed for 5min, centrifuged at 12000 
for 2min and the supernatant transferred to a 1.5ml eppendorff lobind tube. Repeated 
the incubation in RNAse free water once and pooled the samples to 300µl total 
volume. The RNA was then precipitated by adding 30µl of 5M NaAc, 3µl Glycogen 
(10mg/ml), 900µl of absolute ethanol and placing at -20°C overnight. The precipitated 
RNA was then recovered by centrifugation at 13000rpm for 20min and resuspended 
the RNA in 6µl of RNAse free water.  
 
Table 2.2 Oligo-dT cellulose pretreatment protocol 
1. Added 5ml of 0.1M NaOH to 100mg oligo dT cellulose in 15ml tube. Inverted for 
10min at room temperature, then centrifuged for 5min at 5000rpm. 
 
2. Washed cellulose pellet twice with 15ml RNA binding buffer (20mM HEPES, 
pH7.4, 5mM EDTA, pH 7.4, 0.4% SDS, 500mM NaCl) at 5000rpm for 5min.  
 
3. Resuspended the oligodT cellulose in 1ml of RNA binding buffer 
4. Stored the pretreated oligodT cellulose at 4°C 
 
2.4.3 First strand cDNA synthesis  
The cDNA synthesis from the polyA+ RNA was carried out by reverse transcription 
(superscriptIII kit, Invitrogen), using a T3-promoter (5’GCGCGAAATTAACCCTCACT 
AAAGGGAGA 3’) tagged oligo-dT (T3(dT)24) and random nanomer (T3N9) to prime 
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Reagent Conc. Vol. 
RNA Mix  6µl 
T3dT 5pM 1µl 
T3N9 5pM 1µl 
RNAse Out (Inviitrogen) 40U 1µl 
 
Incubated the mix at 65°C for 10min in a thermocycler (Biometra Analytic) and 
placed on ice for 4min. Then added 11µl of the cDNA synthesis mix tabulated below. 
 
RT buffer 10x 2µl 
MgCl2 25mM 4µl 
DTT 0.1M 2µl 
dNTPs 10mM 1µl 
T4gene32 protein (Roche)  1µl 
Superscript III (Invitrogen)  1µl 
 
Incubated at 50°C for 90min, 85°C for 5min, then added 1µl RNase H (2U) and 
incubated at 37°C for 20min. The synthesized cDNA was then purified using the 
RNAeasy mini-elute kit (Qiagen) and eluted in a volume of 12µl with RNAse free 
water. 
2.4.4 Second strand cDNA synthesis  
Trypanosome specific sequences in the trypanosome/WBC (HeLa) mix were 
targeted by specifically priming with the splice leader sequence, SL-4 
(5’GATCTACAGTTTCTGTACTAT3’) which occurs on the 5’ end of every 
trypanosome mRNA. The reaction mix is shown below and the thermo-cycle 
conditions were 98°C for 20sec, 95°C for 1min, 50°C for 60min and 72°C for 60min. 
 
Phusion buffer (Finnzymes) 5X 10µl 
SL-4 primer 0.05pM 1µl 
dNTPs 10mM 1µl 
Phusion Pol (Finnzymes)  1µl 
cDNA mix  12µl 
Nuclease free water  25µl 
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2.4.5 Amplification of the double stranded cDNA 
In order to specifically amplify trypanosome cDNA sequences, a nested PCR using 
the T3-promoter (5’GCGCGAAATTAACCCTCACTAAAGGGAGA3’) and SL20 
(5’ACAGTTTCTGTACTATATTG3’) primers, was carried out. To the second strand 
cDNA synthesis mix was added 1µl of each, SL20 (5pM), T3 (5pM), and Phusion 
polymerase. The PCR conditions were set for 10 cycles of 95°C for 1min, 60°C for 
3min and 72°C for 5min with a final extension at 72°C for 10min. The cDNA was 
purified (QIAquick PCR purification kit, Qiagen) eluted in 30µl and quantified using 
the Qubit 2.0 fluorometer (Invitrogen). 
2.4.6 Radioactive analysis of synthesis 
The second strand synthesis of double stranded cDNA was visualized by the 
incorporation of 25µCi of alpha (32P)-dCTP in the polymerase reaction assay. The 
synthesized DNA was resolved on an 8% Urea acrylamide gel (Table 2.3), exposed 
to a Phosphor-imager screen and analyzed by the Fuji FLA7000. 
The dscDNA was also analysed by in-vitro transcription using the T3 polymerase 
reaction mix (MAXIscript, Ambion Inc.). The reaction was carried out using 12µL of 
the purified dscDNA in a mix consisting of 0.5mM of ATP, CTP, GTP, 50µCi alpha 
(32P)-UTP, 1X transcription buffer, T3 enzyme mix in a final volume of 20µl and 
incubated at 37°C for 10min. The reaction mix was then treated with DNase1, 1µl, 
and continued incubation at 37°C for a further 15min. The synthesized RNA was then 
resolved on an 8% Urea acrylamide gel, exposed to a Phosphor-imager screen and 
analyzed by the Fuji FLA7000. 
 
Table 2.3 8% Urea-acrylamide gel preparation mix 
Reagent Amount 
Urea 39.36g 
Acrylamide 40 (Biorad) 20ml 
TBE, 5X (Trisborate EDTA, pH 8) 18.8ml 
Distilled water 13.4ml 
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2.4.7 High throughput sequencing 
Library preparation of DNA for sequencing was carried out on the cDNA (amplified 
and unamplified), genomic DNA, and the total RNA samples. The cDNA samples 
were first fragmented with the Covaris S2 system (Covaris), using the AFA 
microTube at an Intensity 5, 10% Duty Cycles with 200 cycles per burst for 90 
seconds. A quality check on 1µl of the fragmented sample was done on the 
BioAnalyzer 2100 (Agilent Technologies) using the High Sensitivity chip. The Library 
was then prepared using the NEBNext Ultra DNA Library Prep Kit for Illumina (New 
England BioLabs Inc.). Briefly, end repair, A-tailing and NEBNext singleplex adaptor 
ligation reactions were sequentially carried out on the fragmented DNA. Size 
selection of the adaptor ligated DNA (200 – 250bp) was then carried out using the 
AMPure XP beads followed by product enrichment with a 9 cycle PCR. The amplified 
DNA was cleaned up and 1µl of the library checked on the Bioanalyzer for quality. 
The library was then loaded onto a single lane of the flow cell and run on either the 
Illumina GAII or HiSeq 2000 system for single-end 76bp or 50bp reads respectively. 
The library preparation from genomic DNA was carried out using the same procedure 
as above however, 100bp paired end reads were generated for this case. On the 
other hand, the library preparation from total RNA was carried out using the NEBNext 
Ultra RNA Library Prep Kit for Illumina (New England BioLabs Inc.); and similarly run 
on the HiSeq 2000 system. All the samples were multiplexed. 
2.4.8 Analysis of sequencing data 
The sequenced DNA reads were aligned to the reference T. brucei brucei TREU 927 
genome (TriTrypDB V4.0) using the Bowtie aligner and allowing for 2 mismatches 
(Langmead et al., 2009). All the reads that mapped to the coding sequence (CDS) 
were extracted. For those that did not align, reads containing the spliced leader (SL 
tags) or poly(A) and the T3 promoter were extracted, trimmed and assigned to an 
open reading frame based on their positioning within annotated gene coordinates 
(Fadda et al., 2013). The subsequent processing and sorting of the aligned reads 
was carried out using the SAMtools (Li and Durbin, 2009), and the read alignment to 
the genome visualized by Artemis (Carver et al., 2008; Rutherford et al., 2000). 
DESeq was used to identify differentially expressed genes, with a cutoff p-adjusted 
value of 0.05. Functional category enrichment was carried out using Fisher exact test 
in R. The heat map was generated in R. To plot the average read density along 
genes, we selected around 1000 short genes of 200-1000b in length, and a similar 
number of long ones >2.5kb in length, that had a read coverage of at least 1 on 
average. PERL scripts were written to extract reads aligning to a window of 0.5% of 
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each gene, which were then normalized to the total read count for the gene, and an 
average was plotted against the relative location along 1kb of standardized gene 
length. The gene expression profiles were analyzed as read density per gene and 
expressed as either RPM (reads per million) or RPKM (reads per kilobase per million 
mapped reads). The statistical analysis was carried out using Microsoft excel and R 
(CRAN R-project) tools and the graphs plotted in KaleidaGraph. 
2.4.9 Quantitative Real time PCR analysis  
The expression levels of four genes in the amplified (TH) samples were analyzed by 
real-time quantitative PCR. The amplified cDNA from the 5ng trypanosome to 5µg 
Hela total RNA mix (TH) was used as a template for the qRT-PCR. The qRT-PCR 
was carried out using the SL20 forward primer and the gene specific reverse primer 
annealing downstream of the splice acceptor site within the ORF or 5’ UTR of the 
target gene (Table 2.4). Briefly, 2µl of the amplified cDNA was added to 8µl of the 
master mix (2x SYBR Green, 100pM SL20, 100pM Rev primer) in triplicate in a 96 
well plate. The same was done for the HeLa background control and water template 
negative control. The unamplified trypanosome cDNA template was diluted (1:10, 
100, 500, 1000, 1500, 2000) and 2µl of this used as a template in triplicate for the 
RT-PCR reaction along with the amplified samples. The real time PCR reactions 
were performed using the LightCycler480 (Roche) and the amplifications were done 
using the SYBR Green PCR Master Mix (Roche). The thermal cycling conditions 
were composed of an initial denaturation step at 95ºC for 5 min, 45 cycles at 95°C for 
20s, 60°C for 20s and 72°C for 5s. The experiments were repeated three times (3 
technical replicates) and the relative quantification in gene expression was 
determined using the 2- ΔΔCt method (Schmittgen and Livak 2001, 2008). The fold 
changes in gene expression were normalized by relative expression of the same 
genes from the unamplified trypanosome cDNA (T). 
 
Table 2.4 List of reverse primers for qRT-PCR 
CZ No. Description Sequence 
4438 Tb927.1.2330_rev AGCCTGAACGCAGACGATT 
4432 Tb927.4.4220_rev CCCACAATTGCCACCTTAAA 
4446 Tb927.8.5260_rev TGGTTGGTTCTTGTGTCTGTG 





3.1 Transcriptome of amplified Trypanosome cDNA 
3.1.1 Working hypothesis 
Trypanosomes can be isolated from the buffy coat of infected blood (Woo, 1970), which 
also contains the host white blood cells. The average total RNA yield from adult blood 
samples collected in PAXgene tubes or Tempus tubes is 5µg/ml of blood (Duale et al., 
2012). However, peripheral blood mononuclear cells (PBMC) at a concentration of 106 
cells/ml yield approximately 2µg of total RNA (Eikmans et al., 2013; Marteau et al., 2005). 
We estimated the blood parasitaemia in an infected adult to be about 2000 trypanosomes 
per ml of blood. Since one trypanosome has approximately 0.5pg of total RNA (Haanstra 
et al., 2008), 2000 parasites would yield approximately 1ng of total RNA. Therefore we 
estimated that during active infection, the ratio of human cellular RNA to the Trypanosome 
RNA would be 5ng to 5µg respectively, from 5ml of blood. Based on these estimations, 
there was a need to amplify the trypanosome RNA to the threshold concentration required 
for illumina high throughput sequencing (100ng cDNA). 
Therefore, by mixing trypanosome total RNA with HeLa cell total RNA (5ng:5µg), I 
developed an exponential (PCR based) amplification method to specifically amplify the 
trypanosome cDNA, as illustrated in Fig 3.1 (Kurimoto et al., 2007; Tang et al., 2011). This 
approach utilized the splice leader sequence that is located at the 5’ end of all 
trypanosomatid mRNA following post transcription trans splicing (Liang et al., 2003). With 
this approach, we envisaged a specific enrichment of trypanosome cDNA above the 
human (HeLa) cDNA background to a concentration sufficient for Illumina sequencing. 
3.1.2 Single stranded cDNA synthesis 
Following the selection of polyadenylated RNA (PolyA+ RNA) by oligo(dT) 
chromatography, reverse transcription of this mRNA to cDNA was carried out. The mRNA 
templates were primed with oligo(dT) and random nanomer primers that were modified at 
the 5’ end to contain a promoter sequence of the T3 RNA polymerase, T3(dT)24 and T3N9 
(Eberwine, 1996). The random primers were to capture degraded mRNA and those 
mRNAs that are too long to synthesize full length cDNA using oligo(dT) (Xiang et al., 
2003). The isothermal reverse transcription reaction by Superscrpit III (Invitrogen) was 
maintained at 50°C for maximum efficiency (Malboeuf et al., 2001). The efficiency of cDNA 
synthesis was also enhanced by addition of T4 Gene 32 Protein, which reduces the 
formation of higher order structures of RNA molecules thus reducing any pause sites 




                
 
Figure 3.1 Schematic representation of the trypanosome RNA amplification and sequencing 
workflow. Total RNA extracted from trypanosomes and HeLa cells was mixed at a ratio of 5ng to 
5µg respectively. PolyA+ mRNA was reverse transcribed into cDNA using T3 RNA polymerase 
promoter sequence tagged oligodT and random nanomer primers. The second strand cDNAs were 
synthesised using the splice leader (SL) primer, which targets only the trypanosome cDNA in the 
mix. The double stranded cDNA was then amplified by Nested PCR using the splice leader and T3 
sequence primers, fragmented, and the P1 and P2 adaptors ligated to the ends. The libraries were 
enriched by a PCR, size selected and loaded onto the flow cell for Illumina sequencing. The out put 
reads were then aligned onto the T. brucei genome and transcriptomic analysis of the nanogram 







3.1.3 Second strand cDNA synthesis 
All trypanosome mRNA transcripts have a 39nt splice leader (SL) sequence at their 5’ end 
(Liang et al., 2003). Furthermore, RNASeq analysis carried out on DNA generated by 
second strand synthesis using the splice leader sequence primer was able to map the 5’ 
UTRs of the transcriptome of bloodstream trypanosomes (Kolev et al., 2010; Nilsson et al., 
2010). Therefore in order to specifically detect trypanosome cDNA in the Tryps-HeLa 
cDNA mix, a primer annealing to the splice leader sequence was used to initiate the 
second strand cDNA synthesis by a proofreading Phusion polymerase reaction 
(Finnzymes). In order to optimize this procedure, various primers, concentrations and 
temperature conditions were checked and the results presented are a summary of the 
many experiments that I carried out. 
Following cDNA synthesis by reverse transcription, double stranded DNA was synthesized 
by a splice leader primed DNA polymerase reaction. Different splice leader primers that 
were derived from the full-length splice leader sequence (Fig 3.2A), were used to optimize 
the second strand synthesis conditions. In order to test the sensitivity of these primers for 
trypanosome cDNA in the trypanosome-HeLa mix, 5pM concentration of the primers was 
initially used and the reaction conditions were; denaturation at 95°C for 2min, annealing at 
50°C for 3min and extension at 72°C for 5min (Fig 3.2B). I observed that the SL-4 primer 
had the highest sensitivity with over 3-fold detection of trypanosome cDNA (Fig 3.2B, lane 
10), with minimal HeLa cDNA background as compared to the full-length SL (Fig 3.2B, 
lane 2) and SL20 (Fig 3.2B, lane 6) primers.  
In order to show that these double stranded cDNA transcripts had a T3 promoter 
sequence at the 3’ end, in-vitro transcription using the T3 polymerase was carried out (Fig 
3.2C). RNA transcripts ranging from less than 25 bases to greater than 2 Kb were 
observed, implying that the single strand cDNA and subsequent double stranded cDNA 
synthesis reactions efficiently captured the Trypanosome transcriptome. However it is 
worth noting that the HeLa background (Fig 3.2C, lane 3) could also show transcripts from 
the HeLa transcriptome captured by the two reactions.  
Using the SL-4 primer, the efficiency of the second strand cDNA synthesis was enhanced 
by increasing the annealing and extension times to 60min (Fig 3.2D). I observed that by 
reducing the SL-4 primer concentration to 0.05pM, there was enhanced specificity with a 
5.4 fold increase in detection of the trypanosome cDNA (Fig 3.2D, lane 3) and relatively 
low HeLa cDNA background detection (Fig 3.2D, lane 4). Using these conditions for 
second strand cDNA synthesis, the choice for either OligodT PolyA+ (Amersham) or 
RiboMinus (Invitrogen) selection of mRNA transcripts was checked (Fig 3.2E). The PolyA+ 
method had less HeLa background detection (Fig 3.2E, lane 3) as compared to the 






Figure 3.2 Second strand synthesis of double stranded cDNA in the Trypanosome HeLa mix. 
A. The splice leader sequence primers; SL, full length splice leader, SL20, primer spanning the first 
20bp (from the 3’end) of the full-length, SL-2, primer spanning 20bp after the first 2 bases (TG) of 




B. Second strand synthesis reaction using the splice leader primer and Phusion polymerase 
incorporating the radioisotope α32P-dCTP at 95°C for 2min, 50°C for 3min and 72°C for 5min. The 
dscDNA was run on 8% Urea-polyacrylamide gel, exposed to a phosphor imager and visualised 
using the Fuji FLA7000. 
C. In vitro transcription reaction using T3 polymerase incorporating α32P-dUTP at 37°C for 60min. 
The RNA transcripts were run on 8% Urea-polyacrylamide gel exposed to a phosphor imager.  
D. Second strand synthesis reaction using the SL-4 primer at a concentration of 0.5pM or 0.05pM 
and Phusion polymerase incorporating the radioisotope α32P-dCTP at 95°C for 2min, 50°C for 
60min and 72°C for 60min. 
E. Analysis of OligodT PolyA+ and RiboMinus selection methods of RNA transcripts. 
 
3.1.4 Amplification of double stranded cDNA 
Following second strand dscDNA synthesis, the next step was to amplify the DNA to a 
concentration sufficient for high throughput sequencing. Since the dscDNA was a 
heterogeneous mixture of Trypanosome and HeLa DNA, exponential amplification by PCR 
rather than linear amplification by in vitro transcription (IVT) was opted for (Kurimoto et al., 
2007; Tang et al., 2009).  There was a high HeLa background observed by in vitro 
transcription (Fig 3.2C). Furthermore, there was a lower yield of RNA following in vitro 
transcription and multiple rounds to obtain the required concentration would have 
magnified the background effect. 
First, I tested for which annealing temperature would have the most favourable primer 
hybridization efficiency for the amplification. For this, I used the splice leader primer 
downstream of the SL-4 (second strand synthesis primer) for increased specificity (nested 
primer). Three annealing temperatures, 55°C, 60°C and 65°C, were tested by second 
strand synthesis using the 20mer splice leader primer (Fig 3.3A). Different annealing 
temperatures were analyzed as well. I observed that the annealing temperature of 60°C 
had a 3 fold detection of trypanosome cDNA using 5pM of SL20 primer, in comparison to 
55°C (1 fold) and 65°C (1.6 fold) (Fig 3.3A). It was rather odd that the 60°C was more 
specific than 65°C, but these observations were reproducible. 
The amplification was carried out by the polymerase chain reaction (PCR). For this, the 
number of PCR cycles was set to 10, which would result in approximately 1,024 copies of 
the original DNA (2n, n= No. of cycles). By setting the cycles to a minimum, the effects of 
saturation and amplification bias would also be avoided. The reaction used the high fidelity 
proof reading Phusion DNA polymerase (Finnzymes) with enhanced processivity (Wang et 
al., 2004). The PCR was initiated by adding 5pM of the 20mer splice leader primer (SL-2 
or SL20) in combination with 5pM of T3 promoter sequence primer to the second strand 
synthesis mix. Then, 10 cycles of 95°C for 1min, 60°C for 3min and 72°C for 5min was 
carried out. I observed that the SL20/T3 primer combination had a 2.4 fold enrichment of 
trypanosome amplicons in comparison to the SL-2/T3 combination (Fig 3.3B).  
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Therefore, the overall conditions that were adapted for the amplification protocol were; 
following PolyA+ selection of mRNA, second strand synthesis was carried out using 
0.05pM SL-4 primer under the conditions, 95°C for 2min, 50°C for 60min and 72°C for 
60min. The double stranded cDNA (dscDNA) was then amplified in a 10 cycle Nested 
PCR using 5pM SL20 and T3 primers under the conditions; 95°C for 1min, 60°C for 3min 




Figure 3.3 Amplification of double stranded cDNA in the Trypanosome HeLa mix. 
A. Second strand synthesis reaction using SL20 primer and Phusion polymerase incorporating the 
radioisotope α32P-dCTP at 95°C for 2min, 55°C or 60°C or 65°C for 3min and 72°C for 5min. The 
dscDNA was run on 8% Urea-polyacrylamide gel and exposed to a phosphor imager. 
B. Amplification of dscDNA by 10 cycles of 95°C for 1min, 60°C for 3min and 72°C for 5min with 
Phusion polymerase incorporating the radioisotope α32P-dCTP and amplicons run on 8% Urea-
polyacrylamide gel. A comparison between the primer pairs SL20/T3 and SL-2/T3 at a 
concentration of 5pM was done for this nested PCR. 
 
3.1.5 DNA Sequencing analysis 
Having optimised the RNA amplification protocol, four technical replicates of the 
Trypanosome-HeLA RNA mix (TH, 5ng:5µg) were prepared for high throughput 
sequencing. The amplified DNA amounts of the replicates TH1 and TH2 were 90ng and 
120ng respectively, and were sequenced using the Illumina GAII; TH3 and TH4 were 
sequenced using the Illumina HiSeq2000. In addition, a set up of unamplified trypanosome 
only cDNA (T), obtained by second strand dscDNA synthesis using 5pM SL20 primer (Fig 
3.4A), were prepared for sequencing. In principle, it is the same method as the 
amplification protocol but without the nested PCR step and the use of microgram amounts 
of starting Trypanosome total RNA. Four replicates T1, T2, T3 and T4 with DNA amounts 
of approximately 200ng each were sequenced. T1 and T2 were run on the Illumina GAII 
where as the T3 and T4 samples on the Illumina HiSeq2000. Analysis of the sheared TH 
and T DNA samples (Fig 3.4C) showed an even distribution of fragments that were used 
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for the library preparation. Following the DNA shearing was adaptor ligation and size 
selection. DNA fragments in the range of 300–400bp were hybridised onto the Illumina 
flow cell for sequencing; generating reads that were subsequently analysed. Ibberson, D., 
carried out the library preparation. 
 
3.1.6 Coverage of sequenced reads 
The GAII (76mer) and HiSeq2000 (50mer) reads obtained following Illumina sequencing 
were aligned to the T. b. brucei TREU 927 version 4 reference genome using Bowtie-SAM 
tools (Langmead et al., 2009) and allowing for 2 mismatches (Table 3.1). This was done 
by Fadda A. The average percentage of reads that mapped to the Tb927 genome in the 
amplified Trypanosome – HeLa mix was 2.4% from the GAII and 20.4% using the 
HiSeq2000 system. There was a higher read density with the HiSeq2000 (8.5 fold) and 
hence more reads that were aligned from this platform. The unamplified trypanosome only 
transcriptome also showed a significant difference in the sequencing platforms, the GAII 
having an average of 57.7% and HiSeq with 83.3% reads mapping to the Tb927 genome. 
Considering that the ratio of trypanosome to HeLa RNA was 1:1000, the bulk of the reads 
(80% - 98%) aligned to the Human genome. However the number of genes with greater 
than 2 reads that were detected using a list of 6796 unique single copy ORFs (Siegel et 
al., 2010) were 4346 for the GAII reads. This implied that the transcriptome coverage of 
amplified 5ng of Trypanosome RNA in 5µg of HeLa was 64%. On the other hand, the 
replicate run using the HiSeq2000 system detected all the unique ORFs with 99% 
coverage. This same coverage was observed for the unamplified trypanosome cDNA (T) 
for this unique set of ORFs in both the GAII and HiSeq2000 data sets.  
 
A.  
Illumina GAIIx Unamplified Amplified 
Sample T1 T2 TH1 TH2 
Reads processed 17,790,273 14,796,988 17,909,805 20,350,255 
Reads aligned to CDS 10,348,505 8,379,566 241,924 409,262 
SL, Poly A, T3 tags  67,355 47,367 100,964 117,369 
Total Reads aligned 10,415,860 8,426,933 342,888 586,631 












Illumina HiSeq2000 Unamplified Amplified 
Sample T3 T4 TH3 TH4 
Reads processed 47,539,876 59,769,712 30,889,345 34,076,525 
Reads aligned to CDS 33,441,648 42,639,172 4,585,299 6,508,792 
SL, Poly A, T3 tags  6,143,230 7,228,812 869,722 1,403,415 
Total Reads aligned 39,584,878 49,867,984 5,455,021 7,912,207 
% Reads aligned 83.26% 83.43% 17.66% 23.22% 
 
Table 3.1 Summary of sequenced read output and mapping to the T. brucei TREU 927 reference 
genome. The read output from the Illumina GAII (A) and HiSeq2000 (B) platforms. The samples T1 
and T2, TH1 and TH2 were multiplexed on a single lane of the flow cell, similarly done for T3, T4, 
TH3 and TH4. 
 
 
Although the reads obtained from the amplified (TH) transcriptomes were much less than 
those from the unamplified (T) transcriptomes, they covered the entire 11 chromosome 
genome of T. brucei. I compared the reads from the amplified (TH), unamplified (T) and 
the fragmented PolyA+ RNA (Fig 3.4B) of the bloodstream form 1313 (Manful et al., 2011; 
Roberts et al., 2011) mapping to chromosome 2, 4, 8 and 10 by artemis genome viewer 
(Fig 3.5). I observed that the mapping pattern along the chromosomes was more 
comparable between the amplified (TH) and unamplified (T) transcriptome than the 
BF1313 PolyA+ (Fig 3.5A). Furthermore, the mapping pattern for the HiSeq reads was 
also comparable between the amplified and unamplified transcriptomes, with subtle 
differences in certain regions within the chromosomes (Fig 3.5B). This was probably due 
to the considerable technical similarities in the methodologies for obtaining the 
trypanosome transcriptome from the amplified and unamplified cDNA (Fig 3.1, Fig 3.4A) 





















Figure 3.4 Schematic representation of unamplified Trypanosome RNA library preparation for 
RNASeq. The total RNA from Trypanosomes was subjected to polyA+ selection and either; A. 
Second strand synthesis was carried out on full-length transcripts and then fragmented or B. 
Fragmented the transcripts and carried out the second strand synthesis; this is the reference 
procedure routinely used for RNASeq analysis. C. Aligent bioanalyzer electropherograms of DNA 
sheared by the Covaris. Electophoretic profiles of sheared amplified (TH) Trypanosome-HeLa mix 








Figure 3.5 Artemis visualization of read coverage over entire chromosome. Reads obtained from 
the trypanosome amplified (TH, red), unamplified (T, blue) and polyA+ BF1313 (Green) were 
mapped to the T. brucei TREU 927 reference genome v4. The y-axis is a scale representing the 
read depth of the highest peak of reads. A. Comparison of the GAII reads coverage in all three 
methods on chromosomes 2, 4, 8 and 10, showed a similar pattern between the amplified (TH) and 
unamplified (T). B. Comparison of the HiSeq2000 reads coverage in the amplified (TH) unamplified 
(T) and BF1313 samples. 
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3.1.7 Comparison of transcriptome libraries 
Comparison of replicates 
I compared the sequenced libraries by first, normalising the reads mapped per gene to the 
total mapped reads, hence obtaining the reads per million (RPM); then determined the 
Pearson correlation coefficients (Fig 3.6). The transcriptome profiles between the technical 
replicates that were obtained from either the GAII or the HiSeq2000 were highly similar. 
The correlation coefficients of the amplified (TH) transcriptome replicates were 0.84 and 
0.95 for the GAII and HiSeq2000 libraries respectively (Fig 3.6A, 3.6B). There was low 
correlation for the low abundance transcripts with fewer read counts. A comparison 
between the mean of the TH1 and TH2 libraries and mean of the TH3 and TH4 libraries 
(Fig 3.6C) showed a correlation of 0.79, implying that they had some similarity but with a 
degree of dispersion. However, this low correlation was probably due to the low read 
density from the GAII system, thus fewer genes detected in comparison to the HiSeq2000 
system. There were over 1700 genes that were not represented in the amplification 
experiment sequenced on the GAII system. The correlation coefficients of the unamplified 
(T) transcriptome replicates were 0.92 and 0.93 for the GAII and HiSeq2000 libraries 
respectively (Fig 3.6D, 3.6E). The mean of the T1 and T2 libraries when compared to the 
mean of the T3 and T4 libraries showed a correlation of 0.92 (Fig 3.6F), implying they 
were highly similar. The correlations between the unamplified libraries (T) were better than 
those from the amplified libraries (TH). This was probably because the unamplified library 
started with a high amount of trypanosome only cDNA (200ng) for the sequencing library 
preparation. Since there was no amplification (resulting in bias and artefacts), there was a 
consistent coverage of the entire transcriptome hence the high correlations. This high 
correlation observed within replicates and between the platform (GAII and HiSeq2000) 






Figure 3.6 Scatter plots comparing the transcriptome libraries of the trypanosome amplified (TH) 
and unamplified (T) replicates. Each dot represents a single gene. The degree of similarity between 
libraries was calculated by the Pearson’s correlation coefficient, R. Comparison of reads per million 
(RPM) between technical replicates of the amplified (TH) transcriptomes generated by the GAII (A) 
and HiSeq2000 (B) systems. Comparison of the mean read densities (RPKM) between the GAII 
and HiSeq2000 replicates of the amplified (TH) transcriptomes (C). Comparison of RPM between 
technical replicates of the unamplified (T) transcriptomes generated by the GAII (D) and HiSeq2000 
(E) systems. Comparison of the mean read densities (RPKM) between the GAII and HiSeq2000 




Comparison between libraries 
The read alignment pipeline involved mapping the sequenced output reads to the T. brucei 
genome. These represented reads that mapped to the coding sequence (CDS). The 
unaligned reads were then filtered through for reads having the splice leader sequence 
(SL tag), polyA tag and T3 tag. These reads were then realigned to T. brucei genome and 
the total count of mapped reads was as a summation of CDS, Splice leader tags and 
polyA-T3 tags.  
By using the HiSeq2000 libraries, the mean SL tags from both replicates of the amplified 
(TH) and unamplified (T) libraries were analyzed. The amplified (TH) had 60% (4048/6796) 
SL signatures of the unique genes, with reads greater than or equal to 2. The unamplified 
(T) had 83% (5659/6796) SL signatures with reads greater than or equal to 2. It was also 
observed that the splice leader tags from the amplified (TH) and unamplified (T) 
transcriptome libraries were similar with a high correlation of 0.81 (Fig 3.7A). Furthermore, 
an analysis of the normalised mean per gene read densities (Reads Per Kilobase per 
Million mapped reads, RPKM) between the TH and T showed a high correlation of 0.85 
(Fig 3.7B). This similarity in correlation between the splice leader tags and Rpkms 
indicated that the transcriptome from only 5ng of amplified trypanosome total RNA (TH) 
was comparable and similar to the transcriptome of 200ng unamplified trypanosome cDNA 
(T). However the correlation between the unamplified (T) and the PolyA+ fragmented RNA 
(BF1313) transcriptomes was low, 0.68 (Fig 3.7C). This was also probably due to the 
differences in protocols for obtaining the two libraries, which was also exemplified in the 
read coverage along the genome (Fig 3.5A). Whereas the unamplified trypanosome cDNA 
(T) method involved selection for polyA+ mRNA, cDNA synthesis without RNA 
fragmentation, followed by second strand synthesis using a splice leader primer and then 
fragmentation of the cDNA for library preparation; the BF1313 method involved polyA+ 
selection, fragmentation of the RNA and cDNA library preparation (Figure 3.4A, 3.4B). 
These differences in library preparation could have resulted in the low correlation. 
Furthermore, there was a low correlation between the amplified transcriptome (TH) and 
the polyA+ BF1313, 0.53 (Fig 3.7D). This was probably due to the low starting RNA 
concentration, and technically due the amplification effects and process of library 
preparation. The amplified and unamplified replicates from the HiSeq2000 (Fig 3.7E) and 
GAII (Fig 3.7F) platforms showed a reproducibly similar correlation with the polyA+ 
BF1313. However it is worth noting that the amplified (TH) and unamplified (T) 
trypanosome transcriptomes were more comparable, and this is most probably due to the 
similar technical approach for the selection of splice leader tagged sequences and 






Figure 3.7 Scatter plots comparing the HiSeq2000 transcriptome libraries of the trypanosome 
amplified (TH), unamplified (T) and polyA+ BF1313. Each dot represents a single gene. A. 
Comparison between the means of the amplified (TH) and unamplified (T) splice leader tags. B. 
Comparison between the amplified (TH) and unamplified (T) mean relative gene expression 
profiles. C. Comparison between the unamplified (T) and polyA+ BF1313 gene expression profiles. 
D. Comparison between the amplified (TH) and polyA+ BF1313 relative gene expression profiles. 
Comparison between the amplified (TH) and unamplified (T) with the polyA+ 1313 in the HiSeq (E) 
and GAII (F) libraries.  
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3.1.8 Analysis for amplification bias 
Analysis of RNAseq data has showed that there are tendencies of both positional and 
sequence specific bias in sequenced fragments (Hansen et al., 2010; Srivastava and 
Chen, 2010), which can subsequently affect the gene expression estimates (Li et al., 
2010). Therefore in order to empirically investigate the effect of amplification of nanogram 
concentration of trypanosome RNA transcripts in microgram HeLA RNA background, I 
analysed for the global effect of transcript length bias against the relative gene expression 
(RPKM) was carried out on the HiSeq2000 data (Fig 3.8). I observed that there was a bias 
towards the shorter more highly abundant transcripts in the amplified (TH) transcriptome 
(Fig 3.8A). A similar trend (slope, -1.8) was observed for the unamplified (T) transcriptome 
(Fig 3.8B), suggesting that both methods are comparable in terms of transcript bias. This 
could possibly be due to the biased efficiency of the reverse transcriptase and DNA 
polymerase towards shorter fragments, during synthesis of full length cDNA (5’UTR-CDS-
3’UTR). However, the BF1313 showed no length bias (Fig 3.8C) and this is probably due 
to the fact that the mRNA was fragmented into shorter strands prior to cDNA synthesis; 
resulting in even efficiency of the reverse transcriptase and DNA polymerase for cDNA 
synthesis. But a comparison of all three methods showed that the bulk of transcripts in the 
amplified (TH) and unamplified (T) transcriptomes had comparable gene expression to the 
unbiased BF1313 transcriptome (Figure 3.8D).  
To further investigate transcript length bias on gene expression, I determined the 
frequency distribution of the binned average gene length against their average expression 
(Fig 3.9A). There was high gene expression observed for the short fragments between 
0.03 to 1.5kb in both the amplified (TH) and unamplified (T) in comparison to the polyA+ 
BF1313 transcriptomes. These transcripts account for 38% of genes in the unique list 
(Siegel et al., 2010). This confirmed the observed length bias and this is probably due to 
the reasons explained above. However the transcripts greater than 1.5kb (62%) showed 
an even unbiased distribution of gene expression, a trend that was comparable for all 3 
methods; although the BF1313 showed higher gene expression.  
The length bias at the gene level was determined by Fadda, A., by analysing the read 
densities along a standardised gene length of 1Kb in both the short genes (0.2 – 1Kb) and 
long (greater than 2Kb). There was a uniform distribution of reads for the short genes in all 
three methods (Fig 3.9B) although the amplified (TH) and unamplified (T) genes had a 
short peak of the splice leader reads at the 5’ end. On the other hand, the long genes 
showed a lower coverage of reads in the middle of the gene for the amplified and 
unamplified methods in comparison to the polyA+ sheared BF1313 method (Fig 3.9C). In 
addition, there was observed 5’ end bias with a significantly high peak of reads in this 
region for the amplified and unamplified methods. This was certainly due to the splice 
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leader priming used in these methods. A pronounced 3’ end peak was also observed in 
the unamplified method but neither in the amplified nor BF1313 method. This peak 
corresponds to the T3 priming at the end of the gene, which probably resulted in the 
observed bias. Overall, the observed effects on the short and long genes showed the 
efficiency of the DNA polymerase read through of the full-length genes in the amplified and 
unamplified methods. Whereas the polymerase is highly efficient for the short genes (even 
coverage of reads), it is not efficient for the long genes resulting in the 5’ and 3’ end bias, 
with minimal read coverage in the middle of the gene. The use of the random primers 




Figure 3.8 Scatter plot analysis of the effect of transcript length on the relative gene expression. 
Length vs Rpkm plots of the amplified (TH), A, unamplified (T), B, polyA+ BF1313, C and all three 










Figure 3.9 Analysis of gene length and gene position bias in the amplified, unamplified and polyA+ 
BF1313 transcriptome libraries. A. Histogram showing the frequency distribution of the average 
gene expression (RPKMs) according to there binned gene lengths. * The percentage of the gene 
length category in the total unique ORFs (Siegel et al., 2010). A plot of average relative read 
densities along a standardized gene length of 1kb for a selected group of long genes B, and short 
genes C. Perl scripts were used to extract reads aligning to a window of 0.5% of each gene, which 
were normalized to the total read count of the gene, and an average was plotted against the relative 









3.1.9 Verification of amplification procedure 
In order to check and show that the amplification protocol has worked in samples 
suspected to have trace amounts of trypanosome RNA (such as, Human samples, Rodent 
samples, Tsetse fly samples), there is a need for markers that confirm amplification. 
Therefore a quantitative gene expression analysis was carried out on four candidate 
genes. These genes were selected on basis of length and abundance in the reference 
polyA+ BF1313, and were located on chromosomes 1, 4, 8 and 10. The genes were; long 
transcript with a high RPKM (Tb927.1.2330, beta tubulin, ORF-1329bp, 5’UTR-59bp), long 
transcript with low RPKM (Tb927.4.4220, putative small GTP-binding rab protein, ORF-
1692bp, 5’UTR-1707bp), short transcript with high RPKM (Tb927.8.5260, 60S ribosomal 
protein L39, ORF-156bp, 5’UTR-116bp) and short transcript with low RPKM 
(Tb927.10.8710, putative centrin, ORF-498bp, 5’UTR-108bp) (Fig 3.10A). The long 
abundant beta tubulin showed a high read density across the gene in all 3 methods. 
However for the long less abundant GTP-binding rab transcript, there was a high read 
density bias in the 5’UTR for the amplified (TH) and unamplified (T) methods, with few 
reads in the ORF. This was probably due to the inability of the DNA polymerase to 
efficiently read through the entire 3.4Kb length of this low abundance transcript, hence 
restricted to the 1.7kb of the 5’ UTR following the splice leader priming. On the other hand, 
the polyA+ BF1313 had reads in both the 5’UTR and ORF, since this library was 
generated from randomly sheared mRNA rather than full-length cDNA. The short abundant 
and less abundant transcripts showed an even read density across the gene for all the 
three methods. In general, it was observed in the amplified and unamplified methods that 
almost all the genes had the distinct peak of splice leader reads at the 5’ end as a gene 
signature. Therefore in order to quantitatively validate this observation, the expression of 
these genes in the amplified (TH) samples was determined by quantitative real time PCR 
(Fig 3.10B). The quantitative RT-PCR was carried out using the splice leader forward 
primer (SL20) and the gene specific reverse primer annealing downstream of the splice 
acceptor site within the ORF or 5’ UTR of the target gene. Using the unamplified (T) as 
control cDNA, the relative abundance of the transcripts in the amplified trypanosome (TH) 
samples and amplified HeLa (H) background was determined. There was no observed 
amplification of either transcript in the HeLa control implying that the splice leader and 
gene primers were specific to the trypanosome transcripts and in accordance with the 











Figure 3.10 Gene expression analysis of four transcripts (Tb927.1.2330, Tb927.4.4220, 
Tb927.8.5260, Tb927.10.8710) based on length and abundance. A. Artemis visualization of the 
HiSeq2000 reads (TH4, T4 & BF1313) coverage over the open reading frame (ORF) and un-
translated region (UTR) of the transcripts. B. Quantitative real time PCR on the selected transcripts 
in three separate technical replicates of amplified trypanosome (TH) and HeLa control. The SL20 
forward and gene specific reverse primer were used for each gene. The relative expression level 
was determined using the unamplified trypanosome cDNA (T), error bars indicate standard 





3.2 Transcriptome of T. b. rhodesiense from HAT patients 
3.2.1 Clinical sample collection 
The patient recruitment for the study was carried out at Lwala Hospital, Kaberamaido 
district, which is located in the T. b. rhodesiense focus of North Eastern Uganda. The 
patients were mainly from Kaberamaido and Dokolo districts (Fig 3.11D), which have a 
combined area of 2740km2 and population of approximately 356,500 people (UBOS, 
2010). The annual number of T. b. rhodesiense HAT cases reported from this site in 2010 
and 2011 was 94 and 54 respectively. A total of 60 cases were reported in 2012, however 
for this study, patients were recruited between 1st April and 30th September 2012 and a 
total of 35 case samples were collected during this period (Fig 3.11A). Of these, 23 
showed CNS invasion, 3 were only hemo-lymphatic and 9 were uninfected with T. b. 
rhodesiense. The hospital laboratory staff carried out the screening of suspected HAT 
cases by microscopic detection of motile trypanosomes on a wet blood smear of finger 
prick blood. If trypanosomes were present, a lumbar puncture was performed for disease 
staging. For microscopic detection of trypanosomes in CSF, a pellet obtained after 
centrifugation of the spinal fluid was used (Chappuis et al., 2005). Furthermore, standard 
assessment of co-infections including malaria, filariasis and voluntary testing for HIV/AIDS, 
were carried out. However the patients recruited in the study had neither of these co-
infections detected. Following admission of the patients, the treatment regimen for early 
and late stage T. b. rhodesiense infections were Suramin (Antrypol: Bayer: 20 mg/kg) and 
melarsoprol (MelB) (Arsobal: Rhone-Poulenc: 3.6 mg/kg) respectively for approximately 10 
days. 
A protocol for the sample collection was designed in line with the routine clinical diagnostic 
procedures (Fig 3.11B). The buffy coat and CSF cellular fractions (containing White blood 
cells (WBCs) and Trypanosomes) were counted on a Neubauer haemocytometer and 
reported as cell count per ml (x104/ml). The cell pellets were then resuspended in Trifast 
(PeQlab) and immediately stored in liquid Nitrogen. The sample processing to storage took 
approximately 15min and it is worth noting that the cell counts were done after storage of 
the sample. I trained Ochieng, J., on the above procedure and he carried out the sample 
collection. 
In order to confirm that all case samples collected were indeed T. b. rhodesiense 
infections, I carried out a PCR amplification of the serum resistance associated gene, SRA 
(Radwanska et al., 2002) on the patient blood that had been spotted on Whatman FTA 
cards (Fig 3.11C). All the samples were confirmed for T. b. rhodesiense infection due to 







Figure 3.11 Study sample collection from Sleeping sickness patients. A. Annual HAT cases 
reported at Lwala hospital for the years, 2010, 2011 and 2012. A total of 26 case samples were 
collected for this study in 2012 between the months of April and September. B. Schematic 
representation of the protocol used to process and collect blood and CSF trypanosomes for the 
transcriptome analysis. C. Nested PCR of the SRA gene in DNA extracted from patient blood 
spotted on Whatman FTA cards. The 284 gene fragments confirms presence of T. b. rhodesiense 







3.2.2 Cell count analysis 
Total cellular counts (WBCs and Trypanosomes) were carried out on the buffy coat and 
CSF fractions using a hemocytometer prior to pelleting them (Fig 3.12). The range of 
trypanosomes counted in the 23 patient samples that were analyzed was between 2x104 
and 266x104 cells/ml in the buffy coat. The trypanosome count in the CSF fraction was 
between 0 and 142x104 cells/ml (Fig 3.12A). But given the few cases of outliers who had a 
high trypanosome count, the median count in the buffy coat and CSF fractions was 10x104 
and 6x104 cells/mL respectively (Table 2). On the other hand, the WBC count range was 
between 29 x104 and 960x104 cells/ml in the buffy coat and 5 x104 to 1054 x104 cells/mL in 
the CSF (Fig 3.12B). In this case, the median count for the WBCs in the buffy coat and 
CSF fractions was 284x104 and 54x104 cells/mL respectively (Table 3.2). Except for patient 
LW08A who showed a high trypanosome count and correspondingly high WBC count in 
the buffy coat, there was no observed correlation between trypanosome and WBC counts 
in either buffy coat or CSF. The observed ratio of trypanosomes to WBCs was 1:28 in the 
buffy coat and 1: 9 in the CSF (considering the median count). During the amplification 
protocol development phase, we hypothesized a ratio of 1:1000 and this showed that in 






Figure 3.11D Map of Uganda highlighting 
the disease foci and region from where 
patients where recruited. Lwala hospital is 
located in Kaberamaido district. Samples 
were transported to Makerere University in 
Kampala for processing and further 
analysis. The map is modified from the 





Table 3.2 Summary of cell count data from the 23 patients recruited for the study  
 
Figure 3.12 Dot plot and column graph showing the cell counts in the samples collected from 
patients. A. Shows the cell count of trypanosomes in the buffy coat and CSF samples from the 23 









3.2.3 Sequencing patient samples 
The samples were transported from Uganda to Germany on dry ice for processing and 
sequencing. There was an unexpected delay of the samples at the German customs, at 
which point the ice melted and sampled thawed for a week. 
The total RNA was extracted from the Trifast frozen samples using the chloroform method 
and quantified using the Qubit (Fig 3.13A). The total RNA in the 19 patient samples 
analyzed ranged from 0 to 656ng in the buffy coat fractions and 0 to 580ng in the CSF 
fractions.  There were 13/19 of the samples that had RNA amounts >40ng in the buffy coat 
fractions, where as the CSF fractions had 8/19. However, the amount of RNA obtained 
from the samples was less than expected (Table 3.3). The expected RNA amount for each 
sample was calculated based on Eikmans et al., 2013, who showed that 1x106 peripheral 
blood lymphocytes had an average of 2.8µg total RNA extracted by either Trizol or 
purification columns. This low yield of RNA was probably caused by degradation during 
either storage in Trifast reagent, thawing at the German customs, RNase activity during 
extraction procedure or loss of RNA pellet during the extraction procedure.  
The feasibility of the amplification protocol for the patient samples was tested by second 
strand synthesis to detect trypanosome cDNA in samples LW026A (Fig 3.13B). There was 
detection of trypanosome cDNA in the CSF fraction in comparison to the buffy coat 
fraction, which had less RNA. Furthermore the RNA quality of this LW026A CSF sample 
was checked on the Aligent bioanalyzer (Fig 3.13C) for which traces of Human 28s:18s 
rRNA peaks were detected with a ratio of 1.6, signifying good quality. This suggested that 
the samples were probably not degraded. The amplification protocol was then checked on 
the LW042A buffy coat sample. Analysis of the trypanosome amplified cDNA showed a 
bioanalyser trace of DNA ranging from 300bp to >7kb which covers the entire 
transcriptome as observed in the protocol development phase (Fig 3.13D). The sheared 
cDNA showed a peak between 300 to 500bp that would be used for library preparation for 
sequencing (Fig 3.13E). At this point, library preparations for all the samples were made 
for the sequencing. A total of 21 amplified cDNA samples were processed for sequencing, 
that is, 12 buffy coat, 7 CSF, 1 pool of buffy coat (5 samples <5ng), 1 pool of CSF (10 
samples <5ng).  Unfortunately, except for buffy coat samples LW007 and LW042, the 
profiles from the rest of the samples were extremely variable (Fig 3.14). The majority of the 
samples had distinct peaks with high fluorescent units (concentration). The factors that 
could have affected the yield probably influenced the downstream amplification procedure 
resulting in this variability. However there was an unprecedented failure in making libraries 

































LW002A 2.2 0.13 6.16 ND 5.4 0.16 15.12 ND 
LW006A 5.28 0.08 14.78 78.9 0.8 0.1 2.24 ND 
LW007A 0.96 0.24 2.68 99.4 0.32 0.07 0.91 134 
LW012A 0.29 0.04 0.83 ND 2.45 0.07 6.68 72 
LW020A 9.30 0.06 26.05 42 1.57 0.05 4.40 ND 
LW021A 3.32 0.10 9.29 438 2.24 0.19 6.27 129 
LW022A 4.79 0.02 13.41 656 0.33 0.06 0.94 ND 
LW024A 1.20 0.02 3.36 95.8 0.54 0.03 1.52 73.4 
LW025A 2.84 0.10 7.95 ND 0.68 0.02 1.91 55.6 
LW026A 1.76 0.04 4.92 ND 0.99 0.02 2.77 580 
LW029A 9.12 0.58 25.53 75.4 0.41 0.06 1.14 ND 
LW031A 2.34 0.78 6.56 258 0.44 0.09 1.25 ND 
LW032A 3.02 0.20 8.47 ND 2.08 1 5.82 79.4 
LW036A 9.16 0.05 25.64 ND 0.14 0 0.41 ND 
LW038A 3.64 0.04 10.19 81 1.87 1.42 5.23 54 
LW039A 2.12 0.05 5.93 52 1.29 0.04 3.61 ND 
LW040A 4.68 0.57 13.10 157 0.30 0.03 0.86 ND 
LW041A 1.92 0.64 5.37 56 0.05 0.07 0.14 ND 
LW042A 1.98 2.66 5.54 228 0.11 0.1 0.31 ND 
 
* Expected (Exp.) and Observed (Obs.) RNA amounts in the samples  
* Expected RNA amount calculated from 2.8 ± 0.8 µg/ 1x106 peripheral blood lymphocytes 
(Eikman et al., 2013). 
* ND – Samples with RNA amounts less than 5ng/µl and not detectable by the Qubit. 
 
Table 3.3 Comparison of the expected and observed total RNA amounts from the patient 






Figure 3.13 Analysis of RNA extracted from the patient samples. A. Total amount RNA after Trifast 
(Peqlab) extraction from the patient samples and quantified using the Qubit (Invitrogen). B. 
Detection of trypanosome cDNA in sample LW026A buffy coat and CSF by second strand synthesis 
analysis with α32P-dCTP, resolved on 8% Urea-acrylamide gel and visualised by a phosphor-
imager. C. Agilent Bioanalyzer trace of LW026A CSF-RNA highlighting the 18s and 28s human 
rRNA, showing that the RNA was of good quality. D. Agilent Bioanalyzer trace of amplified LW042A 
buffy coat cDNA showing the range of DNA transcripts. E. Agilent Bioanalyzer trace of the sheared 










Figure 3.14 Agilent bioanalyzer traces of the amplified trypanosome transcriptomes from the 
patient samples. The samples are labelled based on the source, that is buffy coat B or CSF C. The 
y-axis represents a measure of the fluorescence units (FU) and x-axis the coverage in base pairs 






3.3 Transcriptome of purified T. b. rhodesiense trypanosomes  
3.3.1 Comparison of transcriptome libraries 
Besides the buffy coat, there are other methods through which trypanosomes can be 
isolated from blood namely, (a) DEAE cellulose chromatography (Lanham and Godfrey, 
1970; Lonsdale-Eccles and Grab, 1987; Lumsden et al., 1979), in which the blood cells by 
bind to the positively charged DEAE (pH 8) and the trypanosomes are eluted out; (b) Red 
blood cell lysis (Njogu and Kiaira, 1982) followed by centrifugation, with the pellet fraction 
containing the trypanosomes and WBCs. These methods result in 10 times more parasite 
recovery in comparison to the buffy coat method hence could be used in the transcriptome 
analysis avoiding the need for amplification. However the extent to which these methods 
affect the transcriptome of the trypanosomes was not known. By comparing to the buffy 
coat isolated trypanosomes, which don’t undergo any form of purification, I investigated 
the effect of these purification methods on the transcriptome of the bloodstream 
trypanosomes.  
I infected rats with a T. b. rhodesiense strain (Tbr729) and the trypanosomes purified from 
whole blood (Buffy coat, BT, DEAE chromatography, DT, and RBC lysis, RT) for 
transcriptome analysis. Three biological replicates were performed for each isolation 
method, RNA extracted from the purified trypanosomes and processed for HiSeq2000 
sequencing by selecting for the polyA+ RNA transcripts, randomly shearing this RNA 
followed by cDNA synthesis (Fig 3.4B). The library preparation was carried out by 
Ibberson, D., (Fig 3.4B). The number of reads mapping to the open reading frames (ORFs) 
in the T. brucei genome were calculated as reads per kilobase per million mapped reads 
(Rpkm). The data for individual unique open reading frames (ORFs) was then extracted in 
order to eliminate multi-copy ORFs and the transcriptome libraries from the different 
methods were then compared. I observed that the correlation between transcriptome 
libraries of trypanosomes from buffy coat was high (Fig 3.15A & 3.15B), implying that they 
were very similar and highly reproducible. The transcriptome libraries from the DEAE 
purified trypanosomes correlated well between replicates 1 and 2 (Fig 3.15C), however 
there was more distortion observed between replicates 1 and 3 (Fig 3.15D), especially for 
the low abundance transcripts. This suggested that the DEAE purified trypanosome 
transcriptome was not as reproducible as that for the buffy coat trypanosomes. The RBC 
lysis replicates had a high correlation (Fig 3.15E & 3.15F) suggesting a reproducible effect 




          
 
Figure 3.15 Effect of purification on the transcriptome of Trypanosomes. Scatter plot showing the 
correlation between the transcriptomes (RPKMs) of three biological replicates of trypanosomes 
obtained from the buffy coat (BT1, BT2, BT3) A-B, DEAE chromatography (DT1, DT2, DT3), C-D 
and RBC lysis (RT1, RT2, RT3), E-F, of T. b. rhodesiense infected rat blood. Each dot in the scatter 








Further analysis of reproducibility was a measure of the relative standard deviation 
between all three replicates of each isolation method. The mean standard deviations for 
the individual genes were 0.06 for the buffy coat, 0.3 for DEAE and 0.18 for the RBC lysis. 
In addition, it was observed that the buffy coat trypanosomes had 99% of their unique 
genes with relative standard deviation less than 30% (Fig 3.16A); whereas the DEAE (Fig 
3.16B) and the RBC lysis (Fig 3.16C) had 55% and 83% respectively. This certainly 
confirmed that the transcriptomes from the buffy coat trypanosomes were more precise 
and reproducible. The buffy coat pattern was also comparable to that of the in vitro 
cultured bloodstream forms (Fig 3.16D), which also had 99% of their unique genes with 
relative standard deviation less than 30%. The RBC lysis trypanosomes also had a fairly 
reproducible transcriptome however, DEAE purified trypanosome transcriptomes were not 
precisely reproducible. 
 
            
Figure 3.16 Scatter plots relating the percentage relative standard deviation to the mean RPKM of 
each gene (single dot). The mean of the three replicates of each isolation method was used for the 
calculation. Trypanosome transcriptomes obtained by A, Buffy coat, B, DEAE chromatography, C, 




3.3.2 Effect of purification on the transcriptome  
In order to assess the effect of the purification methods on the transcriptome of the 
trypanosomes, I made a comparison between the purified (DEAE and RBC lysis) and 
“unpurified” (buffy coat) trypanosome transcriptomes (Fig 3.17). For this, the mean mRNA 
abundance for each gene in all three replicates was used for the comparison. The 
transcriptome of the DEAE purified trypanosomes had a good correlation with the buffy 
coat trypanosomes except for the low abundant transcripts (Fig 3.17A). However, the RBC 
lysis trypanosomes transcriptome did not correlate well with the buffy coat trypanosomes 
transcriptome, with even more variation observed with the low abundance transcripts (Fig 
3.17A). This seemed to suggest that the DEAE purification procedure did not adversely 
affect the abundance of the transcripts in comparison to the RBC lysis method.  
Furthermore, I analyzed for the expression of transcripts in the DEAE and RBC lysis 
transcriptomes relative to the buffy coat transcriptomes. This was quantified by calculating 
the ratio of the mean RPKMs (unique gene list) from the DEAE and RBC lysis, to the buffy 
coat (DT/BT and RT/BT). By excluding genes with a relative standard deviation greater 
than 50%, it was observed that 20% (1341/6532) of the unique genes in the RBC lysis 
treated trypanosomes showed more than 1.5 fold increase and 23% (1546/6532) had less 
than 0.5 fold decrease in abundance relative to those in the buffy coat. This implied that 
approximately 43% of the transcripts among the unique genes were affected by this 
treatment. On the other hand, for the DEAE treatment, only 1% (74/5655) of the unique 
genes showed 1.5 fold increase whereas none had less than 0.5 fold decrease.  
 
           
 
Figure 3.17 Gene expression analysis between purified and un-purified trypanosomes. 
Scatter plots comparing the average RPKMs of trypanosome transcripts extracted by the buffy 





To further establish the statistical significance of the observed relative expression between 
the methods, Merce, C., carried out a differential gene expression analysis. For this, the 
Fisher’s exact test was used for which the calculated p-values of the transcripts were 
manually assigned functional categories. The functional category enrichment between 
methods was then visualised using a heat map generated in R (Fig 3.18). There were no 
differentially expressed genes detected between the DEAE and Buffy coat methods 
probably because their transcript abundances were quite similar. However there was a 
significant increase in transcripts coding for ribosomal proteins in the RBC lysis treatment. 
Other mRNAs encoding proteins for mitochondrial pathway, chaperones, redox pathway 
and RNA processing were also increased by this treatment. There was also an observed 
decrease in the mRNAs encoding for protein kinases, cytoskeleton, mitochondrial DNA 
metabolism proteins, RNA helicase and many more. This showed that purification by RBC 
lysis greatly affected the transcriptome of the trypanosomes. However, purification by the 
DEAE method did not have such a significant effect on the abundance of mRNAs.  
An analysis of transcripts with an abundance of less than 5 Rpkm showed that 
trypanosomes from the buffy coat had 91, the DEAE, 72 and RBC lysis, 413, out of the 
6773 unique genes. This highlighted the low abundance transcripts that could potentially 
be lost during the course of trypanosome isolation by either method. And indeed the RBC 
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 Figure 3.18 Relative effect of purification methods on transcriptome 
of Trypanosomes. Heat map plot using R of p-values from the 
Fisher’s exact test, showing the enrichment of specific mRNA 
categories in the RBC lysis method relative to the buffy coat or DEAE 
methods. The DEAE method relative to the buffy coat showed no 
specific mRNA enrichment hence not shown. The scale indicates the 
color gradient of p-values with 1 being no effect.    
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3.4 Genomic analysis of T. b. rhodesiense isolates from patients 
3.4.1 Comparison between strain libraries 
In order to investigate the structural variation in the T. b. rhodesiense strains obtained from 
the patients, I inoculated rats with cryopreserved infected blood stabilates in order to 
propagate the parasites for genomic DNA extraction. Four patient isolates, LW024, 
LW031, LW032 and LW041 were selected for DNA sequencing. They were the isolates 
that were able to grow to a density sufficient for genomic DNA extraction. The DNA library 
preparation was carried out by Ibberson, D., multiplexed and sequenced on the Illumina 
HiSeq2000. For comparison, the in vitro cultured T. brucei Lister 427 bloodstream 
(BF1313) and procyclic (Pc2060) forms, and the pleomorphic Antat1.1 were also 
sequenced. These strains express the tet repressor and have been growing in culture 
intermittently since 1990 undergoing clonal selection in the process. The Antat1.1 strain 
has the ability to differentiate into procyclic forms.  
Merce, C., aligned the 100bp reads to the T. brucei TRUE927 reference genome using 
Bowtie2 (Li and Durbin, 2009) and the output is summarized in table 3.3. The reads were 
sorted using the SAM tools (Li et al 2009) and the reads per kilo base per million mapped 
reads (Rpkm) calculated for each transcript. These Rpkm values were used to measure 
the gene copy number and not single nucleotide polymorphisms (SNPs). A comparison 
between the genomes showed a high correlation of 0.99 for the T. b. rhodesiense strains 
obtained from the patients (Fig 3.19 A, B). This implied that the strains were almost 
identical. However there was a lower correlation between the in vitro cultured T. b. brucei 
BF1313 and the field isolated T. b. rhodesiense LW031 implying that there were subtle 
differences between them (Fig 3.19C). A similar phenomenon was observed between the 
pleomorphic Antat1.1 and the T. b. rhodesiense LW031 (Fig 3.19D). The comparison 
between the two cultured strains of the monomorphic BF1313 and pleomorphic Antat1.1 
showed a correlation of 0.95 implying that the two had differences even though they are 
both T. brucei strains (Fig 3.19E). Furthermore, the in vitro cultured BF1313 and procyclic 
form 2060 were more similar (Fig 3.19F) in comparison to the correlation with the Antat1.1 
(Fig 3.19E). The Pc2060 is the differentiated procyclic form of BF1313, hence they have 


















Table 3.3 Summary of sequenced 100bp paired end reads from genomes from Trypanosome 
strains. The patient T. b. rhodesiense isolates (LW031, LW041, LW032, LW024), in vitro cultured T. 
brucei 427 strains, bloodstream form (Bf1313) and procyclic form (Pc2060), and pleomorphic T. 





Figure 3.19 Alignment of genomic reads to the T. brucei 927 reference genome. Correlation of 
Rpkm values between the T. b. rhodesiense isolates from patients LW024 and LW032, A, then 
LW031 and LW041, B. Comparison between the field isolate LW031 and the in vitro cultured T. b. 
brucei bloodstream form BF1313, C, and Antat1.1, D. Comparison between the in vitro cultured T. 









LW031 35,361,888 29,045,683 82% 
LW041 51,994,734 41,540,615 80% 
LW032 54,616,570 43,669,502 80% 
LW024 50,374,813 40,515,524 80% 
Bf1313 35,863,223 28,577,153 79% 
Antat 1.1 32,876,011 24,927,041 76% 
Pc2060 36,864,835 27,162,418 74% 
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3.4.2 Gene copy number variation  
In order to analyze for heterogeneity in the field isolates as well as the laboratory cultured 
strains, the number of copies per gene in the whole genome was determined by Merce, C. 
First was to determine the gene copy number of the reference T. brucei TREU927 
genome. This was carried out by aligning the whole genome sequence reads of T. brucei 
927 (downloaded from the sanger institute data base) to itself (T. brucei TRUE927 
genome) using Bowtie2, allowing 1 and 300 mappings per read (2 alignments, k1 and 
k300). Next was to determine the modal Rpkm value (most frequently occurring Rpkm 
value, Fig 3.20A) that we used to calculate the number of copies per gene, by dividing the 
individual gene Rpkm by this mode value (Rpkm/mode). The reads from the strains were 
then aligned to the TRUE927 reference genome allowing 1 mapping per read and also 
determined the modal value for each strain data set. The gene copy number for each 
strain was then determined relative to the copy number obtained from the reference reads 
alignment.    
Most of the genes in the clinical isolates had the same copy number however there were a 
number of subtle differences observed in the in vitro cultured strains.  The major 
differences in all the isolates were observed in a few selected multi copy genes (Fig 
3.20B). In comparison to all isolates, the cultured strain Bf1313 showed the highest copy 
numbers for the genes encoding the histone proteins (H4, H3, H2A), elongation factor 1-
alpha (TEF1), the chaperone HSP70, paraflagellar rod component (PFR1) and PTP1 
interacting protein (PIP39). The S-adenosylmethionine synthetase, putative (METK1) gene 
showed the same copy number in three of the four field isolates (LW031, LW041, LW032) 
whereas there was one and two extra copies in the Bf1313 and Antat1.1 strains 
respectively. Furthermore, the field isolates also showed differences within these multi-
copy genes implying that they were heterogeneous, in spite of having a high correlation 
between them. The field isolate LW032 had a higher copy number for a number of genes 


















Figure 3.20 Gene copy number variation in T. brucei strains. A. Histogram plot of the frequency of 
gene occurrence against the Rpkm for the reference genome reads, TRUE927. B. Analysis of multi 
copy number genes in the T. b. rhodesiense field isolates (LW031, LW041, LW032, LW024) and T. 




Gene expression studies on African trypanosomes have been carried out by 
high throughput microarrays ((Jensen et al., 2009; Kabani et al. 2009; Queiroz et al. 
2009) or by next generation high throughput sequencing platforms (Nilsson et al., 
2010; Kolev et al., 2010; Siegel et al., 2010 Veitch et al., 2010). These studies were 
done on cultured trypanosomes. This advancement in expression analysis provided 
new insights into the biology of trypanosomes however, the extent to which this 
phenomenon is representative of a real human infection is still not known. Therefore 
this study was aimed at analyzing the transcriptomes of clinical isolates of T. b. 
rhodesiense from sleeping sickness patients using high throughput RNA sequencing 
technology. This transcriptomics approach could be used to study pathophysiological 
mechanisms and identification of disease biomarkers (Le-Niculescu et al., 2009).  
 
4.1 The Transcriptome of T. brucei  
4.1.1 Amplification of nanogram T. brucei RNA in microgram Human RNA 
Clinical samples obtained ex vivo from patients don’t often yield enough RNA 
for high throughput gene expression analysis (Marteau et al., 2005, Mitsuhashi et al., 
2006). During the course of human infection, there are often few circulating 
trypanosomes in the blood and CSF (Mumba Ngoyi et al., 2013). Given this low 
parasitaemia, we hypothesized that the ratio of trypanosome to human cellular total 
RNA in clinical samples of blood or CSF would be 1 to 1000. Therefore in order to 
mimic the amounts in the ex vivo sample, we mixed 5ng of trypanosome total RNA 
with 5µg of HeLa total RNA. But this amount of total RNA was 4000 fold less than 
what was used for the recently published trypanosome high throughput expression 
analysis ((Nilsson et al., 2010; Kolev et al., 2010; Siegel et al., 2010). Hence, there 
was a need to specifically amplify the nanogram amounts of trypanosome RNA in the 
microgram human RNA background to an amount sufficient for the Illumina 
sequencing platform. For this, I rationally designed an exponential amplification 
based method (Iscove et al., 2002, Livesey, 2003) utilizing the splice leader 
sequence located at the 5’ end of all trypanosome mRNA transcripts (Liang et al., 
2003). This amplification-based method has been successfully used to analyze the 
transcriptome of single cells (Kurimoto et al., 2007, Tang et al., 2009, Tang et al., 
2011), so I adapted the same principles to specifically amplify the trypanosome RNA 
from the human RNA background. An alternative method would have been linear 
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amplification by in vitro transcription, IVT (Van Gelder et al., 1990, Stirewalt et al., 
2003). However, there was 1000 fold more HeLa RNA than Trypanosome RNA in the 
heterogeneous mixture and multiple rounds of in vitro transcription would have 
increased this nonspecific background; since all the polyA selected mRNA fragments 
(Trypanosome and HeLa) had the T3 promoter sequence tag at the 3’ end. Another 
reason why this was not the method of choice was that cRNAs less than 1 Kb are 
generated and that every round of IVT can amplify the cDNAs only up to 1000-fold 
(Livesey, 2003, Kawasaki, 2004).  
Having optimized this exponential amplification-based approach, a size 
distribution ranging from 35 base pairs to 10Kb of the amplified cDNAs was traced on 
the bioanalyzer. The smallest gene in the trypanosome is approximately 30bp 
(Tb972.9.15030) coding for the DNA polymerase epsilon subunit b, whereas the 
largest is 19.8kb (Tb927.4.310) coding for a conserved hypothetical protein (tritryp 
db). This suggested that the majority of the expressed genes were captured by the 
developed method, giving a global representation of the transcriptome. This 
observed coverage of genes was probably due to the enhanced full length cDNA 
synthesis procedure which included; use of the tagged random primers (in addition to 
the oligo(dT) primer) and T4gene32 protein, which reduces the formation of higher 
order structures of RNA molecules thus eliminating any pause sites during the 
course of cDNA synthesis  (Rapley, 1994, Villalva et al., 2001, Xiang et al., 2003). 
These factors therefore ensured an efficient read through by the reverse 
transcriptase in synthesis of the cDNA. Furthermore, by using a 21mer splice leader 
oligonucleotide, which is 4 bases upstream of the full length splice leader sequence, 
the specific synthesis of the double stranded cDNA from trypanosome cDNA 
transcripts in the HeLa background was enhanced. The sensitivity of this reaction 
was further improved by lowering the concentration of this splice leader primer and 
prolonging the annealing and extension times to 60 minutes. This adjustment in 
conditions probably enhanced the hybridization and selectivity properties of the 
splice leader primer for trypanosome sequences in the tryphanosome-HeLa mix. By 
using a 20mer splice leader (nested) primer and T3 promoter primer, a 10 cycle PCR 
ensued in specific amplification of trypanosome DNA with a minimal human DNA 
background. Limiting the amplification cycles to 10 was meant to minimize the effects 
of saturation, which would lead to bias towards the more abundant transcripts, 
resulting in loss of proportionality of the amplification process (Wang et al., 2004). 
Overall, this optimized amplification procedure gave an average of 120ng of DNA 




4.1.2 Gene expression analysis of amplified nanogram T. brucei RNA  
Two Illumina platforms that is, Illumina Genome analyzer, GAIIx and Illumina 
HiSeq2000 (http//www.illumina.com) were used to generate reads from the four 
technical replicates of the amplified and unamplified transcriptomes. Overall, the 
replicates from the HiSeq2000 yielded 5 times more reads than the GAIIx. According 
to Illumina, the HiSEq2000 system is shown to have a maximum output of 600Gb 
composed of 3 billion single-end reads whereas the GAIIx has a maximum output of 
95Gb of 320 million single-end reads. This could probably explain the fold difference 
in the replicates between the two platforms. The technical replicates from either 
platform were highly reproducible for both the amplified and unamplified 
transcriptome libraries.  
By considering the HiSeq2000 data, it was observed that over 20% reads 
from the amplified Trypanosoma-HeLa (5ng:5µg) transcriptome library mapped to the 
T. brucei TRUE97 genome, representing a 200-fold enrichment over the input. There 
were as 83% reads of the unamplified trypanosoma transcriptome library that 
mapped to the genome. Even though there was a much less density of reads that 
aligned to the genome from the amplified nanogram RNA trypanosome-HeLa library, 
these reads were able to cover the entire genome with profiles which were 
comparable to the unamplified trypanosome cDNA. Furthermore, the reads obtained 
were not directly proportional to the mRNA abundance, but were instead strongly 
influenced by the splice leader priming and also to a lesser extent, by the PCR 
amplification. The transcriptome libraries from the amplification method were 
reproducible and comparable to the unamplified method but not to the fragmented 
mRNA method. This was probably due to the technical similarity (splice leader 
priming) in the methodologies for generating the trypanosome transcriptome from the 
amplified and unamplified cDNA, as compared to the fragmented RNA method. This 
was suggestive of a methodological bias, which was skewed towards the shorter 
transcripts that are between 0.1 – 1Kb in length. These transcripts had, on average, 
high RPKMs in both amplified and unamplified transcripts, signifying more 
expression relative to the fragmented RNA transcripts. This bias was probably due to 
the enhanced efficiency of the splice leader primed cDNA synthesis by the DNA 
polymerase towards the shorter than the longer fragments.  By analysing a unique 
list of 6772 single copy genes (Siegel et al., 2010), it was observed that 60% of the 
transcripts amplified from the 5ng:5µg trypanosome-HeLa mix had an expression 
threshold of 5 RPKM. The unamplified and fragmented mRNA transcriptomes had 
80% and 98% respectively.  
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 The standard RNASeq approach (fragmented RNA method) gives a direct 
measure of the mRNA abundance (Roberts et al., 2011). In order to obtain “real” 
mRNA abundances from the amplification method, an algorithm would be required to 
simulate and relate the amplified and unamplified transcriptome libraries to the 
fragmented RNA library. Never the less, the amplification method showed ample 
coverage of the transcriptome starting with only 5ng of trypanosome RNA, implying 
that it can be used for samples that contain about 104 parasites. Such is the case 
with T. b. rhodesiense sleeping sickness patients where we observed parasitaemias 
(median) of 1x105 cells/ml and 6x104 cells/ml in the buffy coat and CSF respectively. 
Even much less numbers are observed in the chronic T. b. gambiense sleeping 
sickness patients (Mumba Ngoyi et al., 2013), implying that amplification would be 
inevitable for their transcriptome analysis. In addition, this amplification method could 
be used in the study of other Kinetoplastid natural infections in which the parasites 
have mRNA with a splice leader such as, T. congolense and T. vivax infected cattle, 
and also samples of infected vectors (Tsetse fly, Sand fly). 
4.1.3 Transcriptome of clinical isolates of T. brucei rhodesiense 
Considering the population at risk of T. b. rhodesiense infection in the study 
region (Population of Dokolo and Kaberamaido districts), the prevalence rate was 
reported at 0.017% (60/365,500) in the study period (2012). The average prevalence 
rate reported in the same risk population reported in 2010, 2011 and 2012 was 
0.019%.  In this study, 23 patients were recruited between April and September 
2012. These patient samples had a median trypanosome count of 10x104 and 6x104 
cells/ml in the buffy coat and CSF samples respectively. The routine screening of T. 
b rhodesiense sleeping sickness patients involves microscopic observation of wet 
smears (Chappius et al., 2005). This method resulted in under reporting of the actual 
parasitaemia (5000 parasites/ml of blood), from which we derived our working 
hypothesis at the start of this study. However, we observed a higher parasite count 
than expected because of the concentration by centrifugation for both the buffy coat 
and CSF, before counting on the heamocytometer. The ratio of trypanosomes to 
WBCs was higher in the buffy coat (1:28) than in the CSF (1:9). In addition, there 
was no correlation between the parasitaemia and the WBC count in either buffy coat 
or CSF from the individual patient samples. One would expect a high parasitaemia to 
coincide with a high WBC count following the cellular immune response mounted by 
the patient’s immune system (Sternberg, 2004). However the parasite’s state of 
antigenic variation (Pays et al., 2004) and the poor nutritional status of 90% of the 
patients recruited (Kuepfer et al., 2011), could have resulted in the observed 
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immunodeficiency. However this phenomenon would need to be validated by in 
depth clinical analysis of the individual patients and also cytokine analysis (MacLean 
et al., 2001b; MacLean et al., 2010).  
Buffy coat and CSF cellular pellets from infected patients were collected and 
stored. The time taken for sample collection to storage was 15min, which was crucial 
to avoid RNA degradation ex vivo (Fleige and Pfaffl, 2006). Since we were dealing 
with few cells in the clinical samples, a single extraction reagent (phenol-based Trizol 
Reagent) was used for storage and purification of RNA for subsequent analyses 
(Chomczynski and Sacchi, 2006; Hummon et al., 2007). However, the total RNA 
extracted from the Trifast frozen samples was much less than expected. It was 
assumed that storage of the fresh samples in Trifast reagent (Trizol) could have 
degraded it. However studies have shown that storage of fresh blood cells in trizol 
preserves RNA yield and quality (Eikmans et al., 2013; Kang et al., 2011; Ma et al., 
2010). The prolonged thawing of samples at the German customs could have 
resulted in degradation of the samples. Inadequate shipping and handling of samples 
could easily cause degradation of RNA (Perez-Novo et al., 2005). However an RNA 
check carried out on four samples in Uganda (before shipment) also showed low 
RNA yield. Therefore this meant that the observed low RNA yield was probably due 
to loss of the RNA pellet during the precipitation step of the extraction, or due to 
renatured RNases.  
The other alternatives to the Trizol procedure would be the use of ex vivo 
RNA stabilizing procedures such as the whole blood PAXgene tubes (PreAnalytix, 
Qiagen) for sample collection, transport and storage (Feezor et al., 2004; Rainen et 
al., 2002; Thach et al., 2003). In addition, this PAXgene system enables samples to 
be frozen for up to 2 years without affecting the expression profile (Ovstebo et al., 
2007). Considering the field hospital conditions, the PAXgene system offers an 
advantage since the RNA in whole blood has been shown to be stable at room 
temperature for 5 days, following storage for up to 12 months at -20°C and -80°C, 
and also after repeated freeze-thaw cycles (Rainen et al., 2002). But one 
disadvantage with this method is that, cell counting is not possible because cells are 
lysed directly after collection. In addition, the globin transcripts from the reticulocytes 
may limit the sensitivity of gene expression profiling experiments (Debey et al., 
2004), since these constitute up to 70% of the total whole blood mRNA population 
(Field et al., 2007; Mastrokolias et al., 2012). This would necessitate a globin mRNA 
removal step prior to polyA+ mRNA selection, which might reduce on the overall yield 
of the target RNA.    
Discussion 
 75 
An advantage of total RNA extraction using the Paxgene is that it would yield both 
the trypanosome and lymphocyte transcriptomes. For patient blood samples with a 
parasite: lymphocyte ratio of 1:10 (4x105 : 4x106 cells/ml), total RNA extracted from 
this whole blood and sequenced on a single lane would result in approximately 1 
million reads mapping to the trypanosome. A rather expensive alternative would be 
applying the sequencing library to several lanes to get more reads. But in addition to 
trypanosome transcripts, lymphocyte transcripts from the same sample would also 
be mapped to the human genome hence determining the immunological outcome 
from parasite infection, at the transcriptome level. 
Another alternative to Trizol would be the use of procedures used in isolation 
of RNA from very few/ single cells such as those from laser capture micro dissection 
(LCM), for instance the Picopure RNA isolation kit (Mikulowska-Mennis et al., 2002), 
could be used to recover the required yield of RNA from these clinical buffy coat and 
CFS cell pellets.  
4.2 Effect of purification method on transcriptome of T. b. rhodesiense 
The purification of trypanosomes from blood is employed in parasitological 
confirmation during the diagnosis of trypanosome infections. Increased sensitivity for 
detection is obtained through concentration techniques such as Quantitative buffy 
coat (Ancelle et al., 1997), miniature anion-exchange centrifugation, mAECT  
(Lumsden et al., 1979), and reticulocyte lysis (Njogu and Kiaira, 1982). In addition, 
methods such as DEAE chromatography (similar to mAECT) are used in the 
purification of trypanosomes from host blood in experimental studies of trypanosome 
biology. For the analysis of transcriptomes of trypanosomes from patient blood, 
purification of the trypanosomes would result in increased recovery of parasites and 
certainly reduce on the host’s cells in the sample. The DEAE purification would be 
the method of choice for transcriptome studies since reticulocyte lysis results in 
major distortions in the mRNA abundance. The DEAE purification method can 
therefore be used as an alternative to amplification especially for samples with a 
relatively high parasite count. This method also has the advantage of reducing the 
lymphocyte cellular background from the purified parasites, which would be good for 
those samples with a high WBC to parasite count. Since standard Illumina library 
preparations work best with at least 50ng of mRNA sample, this could be obtained 
from at least 2x106 trypanosomes. However the results from this DEAE purification 
would be less reproducible in comparison to the buffy coat (unpurified) trypanosomes 
from the different patients. Under field conditions in the clinical set up, it would take 
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no less than 40min to process a sample by DEAE purification, whereas the buffy coat 
would conveniently take about 15min.  
4.3 T. b. rhodesiense isolates heterogeneity 
The genomes of four T. b. rhodesiense strains isolated from patients showed that 
even though the sequenced libraries were highly similar, there were variations in the 
gene copy numbers between the isolates. The in vitro cultured T. brucei 427 strains 
had a significant difference to the field isolates with respect to the multi copy genes. 
Most notably were the genes coding for the histone proteins for which there were 5 to 
10 more copies in the cultured T. brucei 427 strains. These proteins play a crucial 
role in transcription initiation and termination (Siegel et al., 2009), and continuous 
culturing of these parasites probably evolved their transcription landscape with 
respect to the in vitro environment resulting in selection of certain growth phenotypes 
(such as, high growth rate, non stumpy formation). Further analysis of structural 
variations in the field isolates was to be carried out. Identifying of single nucleotide 
polymorphisms would enable genotyping these recent isolates and compare them to 
the past isolates from the same disease foci (Goodhead et al., 2013). Furthermore, 
the virulence phenotype of these isolates should have been carried out in a mouse 
infection. This would enable the association of the genotypes with the virulence 
pattern and possibly the clinical picture in the patients. 
4.4 Conclusion 
The splice leader primed amplification method is an approach that can be used to 
determine the transcriptome of Kinetoplastids in the course of natural infection in the 
mammalian or invertebrate host. Sample collection from these hosts should be 
carried out using RNA stabilizing agents since Trizol storage seems to adversely 
affect the transcripts in low cell numbers. Upon generating the mRNA abundance 
profiles, a correction algorithm is then required to relate the amplified libraries to the 
real (unamplified, mRNA fragmented) libraries. This would thus enable the relative 
comparison between different samples. 
 
Manuscript  
Compilation of the methods data into research article for publication; 
Mulindwa, J., Fadda, A., Merce, C., Matovu, E., Enyaru, J., Clayton, C. 2013. 
Methods to determine the transcriptomes of trypanosomes in clinical samples and 







Agranoff, D., A. Stich, P. Abel, and S. Krishna. 2005. Proteomic fingerprinting for the 
diagnosis of human African trypanosomiasis. Trends Parasitol. 21:154-157. 
Aksoy, S. 2003. Control of tsetse flies and trypanosomes using molecular genetics. Vet 
Parasitol. 115:125-145. 
Ancelle, T., A. Paugam, F. Bourlioux, A. Merad, and J.P. Vigier. 1997. [Detection of 
trypanosomes in blood by the Quantitative Buffy Coat (QBC) technique: experimental 
evaluation]. Med Trop (Mars). 57:245-248. 
Apted, F.I.C. 1970. Clinical manifestations and diagnosis of sleeping sickness. In The African 
trypanosomiasis. H.W. Mulligan, editor. George Allen & Unwin, London. 661-683. 
Atouguia, J.L.M., and P.G.E. Kennedy. 2000. Neurological aspects of human African 
trypanosomiasis. In Infectious diseases of the nervous system. L.E. Davis and P.G.E. 
Kennedy, editors. Butterworth-Heinemann, Oxford. 321-372. 
Balasegaram, M., S. Balasegaram, D. Malvy, and P. Millet. 2008. Neglected diseases in the 
news: a content analysis of recent international media coverage focussing on 
leishmaniasis and trypanosomiasis. PLoS neglected tropical diseases. 2:e234. 
Barrett, M. 2010. Potential new drugs for human African trypanosomiasis: some progress at 
last. Curr Opin Infect Dis. 23:603-608. 
Batchelor, N.A., P.M. Atkinson, P.W. Gething, K. Picozzi, E.M. Fèvre, A.S.L. Kakembo, and 
S.C. Welburn. 2009. Spatial predictions of Rhodesian Human African 
Trypanosomiasis (sleeping sickness) prevalence in Kaberamaido and Dokolo, two 
newly affected districts of Uganda. PLoS neglected tropical diseases. 3:e563. 
Berberof, M., D. Perez-Morga, and E. Pays. 2001. A receptor-like flagellar pocket 
glycoprotein specific to Trypanosoma brucei gambiense. Molecular and biochemical 
parasitology. 113:127-138. 
Berriman, M., E. Ghedin, C. Hertz-Fowler, G. Blandin, H. Renauld, D.C. Bartholomeu, N.J. 
Lennard, E. Caler, N.E. Hamlin, B. Haas, U. Bohme, L. Hannick, M.A. Aslett, J. 
Shallom, L. Marcello, L. Hou, B. Wickstead, U.C. Alsmark, C. Arrowsmith, R.J. Atkin, 
A.J. Barron, F. Bringaud, K. Brooks, M. Carrington, I. Cherevach, T.J. Chillingworth, 
C. Churcher, L.N. Clark, C.H. Corton, A. Cronin, R.M. Davies, J. Doggett, A. Djikeng, 
T. Feldblyum, M.C. Field, A. Fraser, I. Goodhead, Z. Hance, D. Harper, B.R. Harris, 
H. Hauser, J. Hostetler, A. Ivens, K. Jagels, D. Johnson, J. Johnson, K. Jones, A.X. 
Kerhornou, H. Koo, N. Larke, S. Landfear, C. Larkin, V. Leech, A. Line, A. Lord, A. 
Macleod, P.J. Mooney, S. Moule, D.M. Martin, G.W. Morgan, K. Mungall, H. 
Norbertczak, D. Ormond, G. Pai, C.S. Peacock, J. Peterson, M.A. Quail, E. 
Rabbinowitsch, M.A. Rajandream, C. Reitter, S.L. Salzberg, M. Sanders, S. Schobel, 
S. Sharp, M. Simmonds, A.J. Simpson, L. Tallon, C.M. Turner, A. Tait, A.R. Tivey, S. 
Van Aken, D. Walker, D. Wanless, S. Wang, B. White, O. White, S. Whitehead, J. 
Woodward, J. Wortman, M.D. Adams, T.M. Embley, K. Gull, E. Ullu, J.D. Barry, A.H. 
Fairlamb, F. Opperdoes, B.G. Barrell, J.E. Donelson, N. Hall, C.M. Fraser, et al. 
2005. The genome of the African trypanosome Trypanosoma brucei. Science. 
309:416-422. 
Biéler, S., E. Matovu, P. Mitashi, E. Ssewannyana, S.K.B. Shamamba, P.R. Bessell, and J.M. 
Ndung&apos;u. 2012. Improved detection of Trypanosoma brucei by lysis of red 
blood cells, concentration and LED fluorescence microscopy. Acta Tropica. 121:135-
140. 
Brady, G., M. Barbara, and N.N. Iscove. 1990. Representative in vitro cDNA amplification 
from individual hemopoietic cells and colonies. Methods Mol. Cell. Biol. 2:17-25. 
Brun, R., J. Blum, F. Chappuis, and C. Burri. 2010. Human African trypanosomiasis. Lancet. 
375:148-159. 
Brun, R., R. Don, R.T. Jacobs, M.Z. Wang, and M.P. Barrett. 2011. Development of novel 
drugs for human African trypanosomiasis. Future Microbiol. 6:677-691. 
Bucheton, B., A. Macleod, and V. Jamonneau. 2011. Human host determinants influencing 




Burri, C., and R. Brun. 2003. Eflornithine for the treatment of human African trypanosomiasis. 
Parasitology research. 90 Supp 1:S49-52. 
Büscher, P., V. Lejon, E. Magnus, and N. Van Meirvenne. 1999. Improved latex agglutination 
test for detection of antibodies in serum and cerebrospinal fluid of Trypanosoma 
brucei gambiense infected patients. Acta Tropica. 73:11-20. 
Capewell, P., N.J. Veitch, C.M.R. Turner, J. Raper, M. Berriman, S.L. Hajduk, and A. 
Macleod. 2011. Differences between Trypanosoma brucei gambiense Groups 1 and 
2 in Their Resistance to Killing by Trypanolytic Factor 1. PLoS neglected tropical 
diseases. 5:e1287. 
Carter, N.S., B.J. Berger, and A.H. Fairlamb. 1995. Uptake of diamidine drugs by the P2 
nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei 
brucei. J Biol Chem. 270:28153-28157. 
Carver, T., M. Berriman, A. Tivey, C. Patel, U. Böhme, B.G. Barrell, J. Parkhill, and M.-A. 
Rajandream. 2008. Artemis and ACT: viewing, annotating and comparing sequences 
stored in a relational database. …. 
Cattand, P. 2001. The epidemiology of human African trypanosomiasis: a complex 
multifactorial history. Med Trop (Mars). 61:313-322. 
Chappuis, F., L. Loutan, P. Simarro, V. Lejon, and P. Buscher. 2005. Options for field 
diagnosis of human african trypanosomiasis. Clin Microbiol Rev. 18:133-146. 
Checchi, F., J.A. Filipe, D.T. Haydon, D. Chandramohan, and F. Chappuis. 2008. Estimates 
of the duration of the early and late stage of gambiense sleeping sickness. BMC 
infectious diseases. 8:16. 
Chomczynski, P., and N. Sacchi. 2006. The single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. 
Nat Protoc. 1:581-585. 
Clayton, C., and M. Shapira. 2007. Post-transcriptional regulation of gene expression in 
trypanosomes and leishmanias. Mol Biochem Parasitol. 156:93-101. 
Connor, R.J. 1994. The impact of nagana. The Onderstepoort journal of veterinary research. 
61:379-383. 
Croft, S.L., M.P. Barrett, and J.A. Urbina. 2005. Chemotherapy of trypanosomiases and 
leishmaniasis. Trends in parasitology. 21:508-512. 
Daniels, J.P., K. Gull, and B. Wickstead. 2010. Cell biology of the trypanosome genome. 
Microbiology and molecular biology reviews : MMBR. 74:552-569. 
Das, A., Q. Zhang, J.B. Palenchar, B. Chatterjee, G.A. Cross, and V. Bellofatto. 2005. 
Trypanosomal TBP functions with the multisubunit transcription factor tSNAP to direct 
spliced-leader RNA gene expression. Molecular and cellular biology. 25:7314-7322. 
De Greef, C., and R. Hamers. 1994. The serum resistance-associated (SRA) gene of 
Trypanosoma brucei rhodesiense encodes a variant surface glycoprotein-like protein. 
Molecular and biochemical parasitology. 68:277-284. 
Debey, S., U. Schoenbeck, M. Hellmich, B.S. Gathof, R. Pillai, T. Zander, and J.L. Schultze. 
2004. Comparison of different isolation techniques prior gene expression profiling of 
blood derived cells: impact on physiological responses, on overall expression and the 
role of different cell types. The pharmacogenomics journal. 4:193-207. 
Deborggraeve, S., M. Koffi, V. Jamonneau, F.A. Bonsu, R. Queyson, P.P. Simarro, P. 
Herdewijn, and P. Buscher. 2008. Molecular analysis of archived blood slides reveals 
an atypical human Trypanosoma infection. Diagnostic microbiology and infectious 
disease. 61:428-433. 
Dempsey, W.L., and J.M. Mansfield. 1983. Lymphocyte function in experimental African 
trypanosomiasis. V. Role of antibody and the mononuclear phagocyte system in 
variant-specific immunity. Journal of immunology. 130:405-411. 
Despommier, D., R. Gwardz, P. Hotez, and C. Knirsch. 2005. Parasitic diseases. Apple trees 
productions, L.L.C, New York. 
Duale, N., G. Brunborg, K.S. Rønningen, T. Briese, J. Aarem, K.K. Aas, P. Magnus, C. 
Stoltenberg, E. Susser, and W.I. Lipkin. 2012. Human blood RNA stabilization in 
samples collected and transported for a large biobank. BMC research notes. 5:510. 
Duggan, A.J., and M.P. Hutchinson. 1966. Sleeping sickness in Europeans: a review of 109 
cases. J Trop Med Hyg. 69:124-131. 
Dukes, P., W.C. Gibson, J.K. Gashumba, K.M. Hudson, T.J. Bromidge, A. Kaukus, T. 
Asonganyi, and E. Magnus. 1992. Absence of the LiTat 1.3 (CATT antigen) gene in 
Trypanosoma brucei gambiense stocks from Cameroon. Acta Tropica. 51:123-134. 
References 
 79 
Dumas, M., J.C. Breton, M. Pestre Alexandre, P.L. Girard, and C. Giordano. 1985. Current 
status of the therapy of human African trypanosomiasis. Presse Med. 14:253-256. 
Eberwine, J. 1996. Amplification of mRNA populations using aRNA generated from 
immobilized oligo(dT)-T7 primed cDNA. BioTechniques:584-594. 
Eberwine, J., H. Yeh, K. Miyashiro, Y. Cao, S. Nair, R. Finnell, M. Zettel, and P. Coleman. 
1992. Analysis of gene expression in single live neurons. Proceedings of the National 
Academy of Sciences of the United States of America. 89:3010-3014. 
Eikmans, M., N.V. Rekers, J.D.H. Anholts, S. Heidt, and F.H.J. Claas. 2013. Blood cell 
mRNAs and microRNAs: optimized protocols for extraction and preservation. Blood. 
121:e81-89. 
El-Sayed, N.M., P. Hegde, J. Quackenbush, S.E. Melville, and J.E. Donelson. 2000. The 
African trypanosome genome. Int. J. Parasitol. 30:329-345. 
Enyaru, J.C., E. Matovu, M. Akol, C. Sebikali, J. Kyambadde, C. Schmidt, R. Brun, R. 
Kaminsky, L.M. Ogwal, and F. Kansiime. 1998. Parasitological detection of 
Trypanosoma brucei gambiense in serologically negative sleeping-sickness suspects 
from north-western Uganda. Annals of tropical medicine and parasitology. 92:845-
850. 
Ersfeld, K., S.E. Melville, and K. Gull. 1999. Nuclear and genome organization of 
Trypanosoma brucei. Parasitol. Today. 15:58-63. 
Fadda, A., V. Farber, D. Droll, and C. Clayton. 2013. The roles of 3'-exoribonucleases and the 
exosome in trypanosome mRNA degradation. RNA. 19:937-947. 
Fairbairn, H., and D.G. Godfrey. 1957. The local reaction in man at the site of infection with 
Trypanosoma rhodesiense. Ann Trop Med Parasitol. 51:464-470. 
Fairlamb, A.H. 2003. Chemotherapy of human African trypanosomiasis: current and future 
prospects. Trends in parasitology. 19:488-494. 
Fairlamb, A.H., and I.B. Bowman. 1980. Uptake of the trypanocidal drug suramin by 
bloodstream forms of Trypanosoma brucei and its effect on respiration and growth 
rate in vivo. Mol Biochem Parasitol. 1:315-333. 
Fairlamb, A.H., and A. Cerami. 1992. Metabolism and functions of trypanothione in the 
Kinetoplastida. Annu. Rev. Microbiol. 46:695-729. 
Fairlamb, A.H., G.B. Henderson, and A. Cerami. 1989. Trypanothione is the primary target for 
arsenical drugs against African trypanosomiasis. Proc. Natl. Acad. Sci. USA. 
86:2607-2611. 
Feezor, R.J., H.V. Baker, M. Mindrinos, D. Hayden, C.L. Tannahill, B.H. Brownstein, A. Fay, 
S. MacMillan, J. Laramie, W. Xiao, L.L. Moldawer, J.P. Cobb, K. Laudanski, C.L. 
Miller-Graziano, R.V. Maier, D. Schoenfeld, R.W. Davis, R.G. Tompkins, 
Inflammation, and L.-S.C.R.P. Host Response to Injury. 2004. Whole blood and 
leukocyte RNA isolation for gene expression analyses. Physiol Genomics. 19:247-
254. 
Fernández-Moya, S.M., and A.M. Estévez. 2010. Posttranscriptional control and the role of 
RNA-binding proteins in gene regulation in trypanosomatid protozoan parasites. 
Wiley interdisciplinary reviews. RNA. 1:34-46. 
Field, L.A., R.M. Jordan, J.A. Hadix, M.A. Dunn, C.D. Shriver, R.E. Ellsworth, and D.L. 
Ellsworth. 2007. Functional identity of genes detectable in expression profiling assays 
following globin mRNA reduction of peripheral blood samples. Clin Biochem. 40:499-
502. 
Figueiredo, L.M., G.A.M. Cross, and C.J. Janzen. 2009. Epigenetic regulation in African 
trypanosomes: a new kid on the block. Nature Publishing Group. 7:504-513. 
Fleige, S., and M.W. Pfaffl. 2006. RNA integrity and the effect on the real-time qRT-PCR 
performance. Molecular aspects of medicine. 27:126-139. 
Fu, X., N. Fu, S. Guo, Z. Yan, Y. Xu, H. Hu, C. Menzel, W. Chen, Y. Li, R. Zeng, and P. 
Khaitovich. 2009. Estimating accuracy of RNA-Seq and microarrays with proteomics. 
BMC genomics. 10:161. 
Gibson, W., T. Backhouse, and A. Griffiths. 2002. The human serum resistance associated 
gene is ubiquitous and conserved in Trypanosoma brucei rhodesiense throughout 
East Africa. Infection, genetics and evolution : journal of molecular epidemiology and 
evolutionary genetics in infectious diseases. 1:207-214. 
Glover, L., and D. Horn. 2006. Repression of polymerase I-mediated gene expression at 
Trypanosoma brucei telomeres. EMBO Rep. 7:93-99. 
References 
 80 
Goodhead, I., P. Capewell, J.W. Bailey, T. Beament, M. Chance, S. Kay, S. Forrester, A. 
Macleod, M. Taylor, H. Noyes, and N. Hall. 2013. Whole-Genome Sequencing of 
Trypanosoma brucei Reveals Introgression between Subspecies That Is Associated 
with Virulence. mBio. 4. 
Greenwood, B.M., and H.C. Whittle. 1980. The pathogenesis of sleeping sickness. Trans R 
Soc Trop Med Hyg. 74:716-725. 
Gunzl, A., T. Bruderer, G. Laufer, B. Schimanski, L.C. Tu, H.M. Chung, P.T. Lee, and M.G. 
Lee. 2003. RNA polymerase I transcribes procyclin genes and variant surface 
glycoprotein gene expression sites in Trypanosoma brucei. Eukaryot Cell. 2:542-551. 
Haanstra, J.R., M. Stewart, V.D. Luu, A. van Tuijl, H.V. Westerhoff, C. Clayton, and B.M. 
Bakker. 2008. Control and regulation of gene expression: quantitative analysis of the 
expression of phosphoglycerate kinase in bloodstream form Trypanosoma brucei. 
The Journal of biological chemistry. 283:2495-2507. 
Hansen, K.D., S.E. Brenner, and S. Dudoit. 2010. Biases in Illumina transcriptome 
sequencing caused by random hexamer priming. Nucleic acids research. 38:e131. 
Hecker, H., B. Betschart, M. Burri, and W. Schlimme. 1995. Functional morphology of 
trypanosome chromatin. Parasitology Today. 11:79. 
Henry, M.C., P. Kageruka, J.F. Ruppol, H. Bruneel, and Y. Claes. 1981. Evaluation of field 
diagnosis of trypanosomiasis caused by Trypanosoma brucei gambiense. Ann Soc 
Belg Med Trop. 61:79-92. 
Hertz, C.J., H. Filutowicz, and J.M. Mansfield. 1998. Resistance to the African trypanosomes 
is IFN-gamma dependent. J Immunol. 161:6775-6783. 
Hummon, A.B., S.R. Lim, M.J. Difilippantonio, and T. Ried. 2007. Isolation and solubilization 
of proteins after TRIzol extraction of RNA and DNA from patient material following 
prolonged storage. Biotechniques. 42:467-470, 472. 
Hutchinson, O.C., H. Webb, K. Picozzi, S. Welburn, and M. Carrington. 2004. Candidate 
protein selection for diagnostic markers of African trypanosomiasis. Trends Parasitol. 
20:519-523. 
Iscove, N.N., M. Barbara, M. Gu, M. Gibson, C. Modi, and N. Winegarden. 2002. 
Representation is faithfully preserved in global cDNA amplified exponentially from 
sub-picogram quantities of mRNA. Nat Biotechnol. 20:940-943. 
Jackson, A.P., M. Sanders, A. Berry, J. McQuillan, M.A. Aslett, M.A. Quail, B. Chukualim, P. 
Capewell, A. Macleod, S.E. Melville, W. Gibson, J.D. Barry, M. Berriman, and C. 
Hertz-Fowler. 2010. The genome sequence of Trypanosoma brucei gambiense, 
causative agent of chronic human african trypanosomiasis. PLoS neglected tropical 
diseases. 4:e658. 
Jacobs, R.T., B. Nare, S.A. Wring, M.D. Orr, D. Chen, J.M. Sligar, M.X. Jenks, R.A. Noe, T.S. 
Bowling, L.T. Mercer, C. Rewerts, E. Gaukel, J. Owens, R. Parham, R. Randolph, B. 
Beaudet, C.J. Bacchi, N. Yarlett, J.J. Plattner, Y. Freund, C. Ding, T. Akama, Y.K. 
Zhang, R. Brun, M. Kaiser, I. Scandale, and R. Don. 2011a. SCYX-7158, an Orally-
Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis. 
PLoS Negl Trop Dis. 5:e1151. 
Jacobs, R.T., J.J. Plattner, B. Nare, S.A. Wring, D. Chen, Y. Freund, E.G. Gaukel, M.D. Orr, 
J.B. Perales, M. Jenks, R.A. Noe, J.M. Sligar, Y.K. Zhang, C.J. Bacchi, N. Yarlett, 
and R. Don. 2011b. Benzoxaboroles: a new class of potential drugs for human 
African trypanosomiasis. Future Med Chem. 3:1259-1278. 
Jamonneau, V., H. Ilboudo, J. Kabore, D. Kaba, M. Koffi, P. Solano, A. Garcia, D. Courtin, C. 
Laveissiere, K. Lingue, P. Buscher, and B. Bucheton. 2012. Untreated human 
infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop 
Dis. 6:e1691. 
Jensen, B.C., D. Sivam, C.T. Kifer, P.J. Myler, and M. Parsons. 2009. Widespread variation in 
transcript abundance within and across developmental stages of Trypanosoma 
brucei. BMC Genomics. 10:482. 
Joshi, P.P., V.R. Shegokar, R.M. Powar, S. Herder, R. Katti, H.R. Salkar, V.S. Dani, A. 
Bhargava, J. Jannin, and P. Truc. 2005. Human trypanosomiasis caused by 
Trypanosoma evansi in India: the first case report. The American journal of tropical 
medicine and hygiene. 73:491-495. 
Kabani, S., K. Fenn, A. Ross, A. Ivens, T.K. Smith, P. Ghazal, and K. Matthews. 2009. 
Genome-wide expression profiling of in vivo-derived bloodstream parasite stages and 
References 
 81 
dynamic analysis of mRNA alterations during synchronous differentiation in 
Trypanosoma brucei. BMC genomics. 10:427. 
Kaiser, M., M.A. Bray, M. Cal, B. Bourdin Trunz, E. Torreele, and R. Brun. 2011. 
Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate 
for Treatment of Sleeping Sickness. Antimicrobial Agents and Chemotherapy. 
55:5602-5608. 
Kalisky, T., P. Blainey, and S.R. Quake. 2011. Genomic analysis at the single-cell level. Annu 
Rev Genet. 45:431-445. 
Kang, J.-E., S.-H. Hwang, J.H. Lee, D.Y. Park, and H.-H. Kim. 2011. Effects of RBC removal 
and TRIzol of peripheral blood samples on RNA stability. Clinica chimica acta; 
international journal of clinical chemistry. 412:1883-1885. 
Kawasaki, E.S. 2004. Microarrays and the gene expression profile of a single cell. Ann N Y 
Acad Sci. 1020:92-100. 
Kazyumba, G., M. Berney, G. Brighouse, A. Cruchaud, and P.H. Lambert. 1986. Expression 
of the B cell repertoire and autoantibodies in human African trypanosomiasis. Clinical 
and experimental immunology. 65:10-18. 
Kennedy, P.G. 2008. The continuing problem of human African trypanosomiasis (sleeping 
sickness). Ann Neurol. 64:116-126. 
Kennedy, P.G. 2012. An alternative form of melarsoprol in sleeping sickness. Trends in 
parasitology. 28:307-310. 
Kennedy, P.G.E. 2004. Human African trypanosomiasis of the CNS: current issues and 
challenges. The Journal of clinical investigation. 113:496-504. 
Kieft, R., N.A. Stephens, P. Capewell, A. Macleod, and S.L. Hajduk. 2012. Role of expression 
site switching in the development of resistance to human Trypanosome Lytic Factor-1 
in Trypanosoma brucei brucei. Molecular and biochemical parasitology. 183:8-14. 
Klur, S., K. Toy, M.P. Williams, and U. Certa. 2004. Evaluation of procedures for amplification 
of small-size samples for hybridization on microarrays. Genomics. 83:508-517. 
Kolev, N.G., J.B. Franklin, S. Carmi, H. Shi, S. Michaeli, and C. Tschudi. 2010. The 
transcriptome of the human pathogen Trypanosoma brucei at single-nucleotide 
resolution. PLoS pathogens. 6:e1001090. 
Krafsur, E.S. 2009. Tsetse flies: genetics, evolution, and role as vectors. Infection, genetics 
and evolution : journal of molecular epidemiology and evolutionary genetics in 
infectious diseases. 9:124-141. 
Kuboki, N., N. Inoue, T. Sakurai, F. Di Cello, D.J. Grab, H. Suzuki, C. Sugimoto, and I. 
Igarashi. 2003. Loop-mediated isothermal amplification for detection of African 
trypanosomes. Journal of clinical microbiology. 41:5517-5524. 
Kuepfer, I., E.P. Hhary, M. Allan, A. Edielu, C. Burri, and J.A. Blum. 2011. Clinical 
presentation of T.b. rhodesiense sleeping sickness in second stage patients from 
Tanzania and Uganda. PLoS neglected tropical diseases. 5:e968. 
Kuepfer, I., C. Schmid, M. Allan, A. Edielu, E.P. Haary, A. Kakembo, S. Kibona, J. Blum, and 
C. Burri. 2012. Safety and efficacy of the 10-day melarsoprol schedule for the 
treatment of second stage Rhodesiense sleeping sickness. PLoS neglected tropical 
diseases. 6:e1695. 
Kurimoto, K., Y. Yabuta, Y. Ohinata, Y. Ono, K.D. Uno, R.G. Yamada, H.R. Ueda, and M. 
Saitou. 2006. An improved single-cell cDNA amplification method for efficient high-
density oligonucleotide microarray analysis. Nucleic acids research. 34:e42. 
Kurimoto, K., Y. Yabuta, Y. Ohinata, and M. Saitou. 2007. Global single-cell cDNA 
amplification to provide a template for representative high-density oligonucleotide 
microarray analysis. Nature protocols. 2:739-752. 
Kuzoe, F.A. 1993. Current situation of African trypanosomiasis. Acta Tropica. 54:153-162. 
Lambert, P.H., M. Berney, and G. Kazyumba. 1981. Immune complexes in serum and in 
cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell 
activation and with intracerebral immunoglobulin synthesis. The Journal of clinical 
investigation. 67:77-85. 
Langmead, B., C. Trapnell, M. Pop, and S.L. Salzberg. 2009. Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome biology. 10:R25. 
Lanham, S.M., and D.G. Godfrey. 1970. Isolation of salivarian trypanosomes from man and 
other mammals using DEAE-cellulose. Exp Parasitol. 28:195-202. 
Le-Niculescu, H., S.M. Kurian, N. Yehyawi, C. Dike, S.D. Patel, H.J. Edenberg, M.T. Tsuang, 
D.R. Salomon, J.I. Nurnberger, Jr., and A.B. Niculescu. 2009. Identifying blood 
References 
 82 
biomarkers for mood disorders using convergent functional genomics. Molecular 
psychiatry. 14:156-174. 
Legros, D., S. Evans, F. Maiso, J. Enyaru, and D. Mbulamberi. 1999. Risk factors for 
treatment failure after melarsoprol for Trypanosoma brucei gambiense 
trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 93:439-442. 
Lejon, V., P. Buscher, E. Magnus, A. Moons, I. Wouters, and N. Van Meirvenne. 1998. A 
semi-quantitative ELISA for detection of Trypanosoma brucei gambiense specific 
antibodies in serum and cerebrospinal fluid of sleeping sickness patients. Acta 
Tropica. 69:151-164. 
Lejon, V., J. Lardon, G. Kenis, L. Pinoges, D. Legros, S. Bisser, X. N'Siesi, E. Bosmans, and 
P. Büscher. 2002a. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of 
Trypanosoma brucei gambiense sleeping sickness patients before and after 
treatment. Trans R Soc Trop Med Hyg. 96:329-333. 
Lejon, V., D. Legros, M. Richer, J.A. Ruiz, V. Jamonneau, P. Truc, F. Doua, N. Dje, F.X. 
N'Siesi, S. Bisser, E. Magnus, I. Wouters, J. Konings, T. Vervoort, F. Sultan, and P. 
Buscher. 2002b. IgM quantification in the cerebrospinal fluid of sleeping sickness 
patients by a latex card agglutination test. Tropical medicine & international health : 
TM & IH. 7:685-692. 
Li, H., and R. Durbin. 2009. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics. 25:1754-1760. 
Li, J., H. Jiang, and W.H. Wong. 2010. Modeling non-uniformity in short-read rates in RNA-
Seq data. Genome biology. 11:R50. 
Liang, X., A. Haritan, S. Uliel, and S. Michaeli. 2003. Trans and cis splicing in 
trypanosomatids: mechanism, factors, and regulation. Euk. Cell. 2:830-840. 
Liu, Y., S.A. Motyka, and P.T. Englund. 2005. Effects of RNA interference of Trypanosoma 
brucei structure-specific endonuclease-I on kinetoplast DNA replication. The Journal 
of biological chemistry. 280:35513-35520. 
Livesey, F.J. 2003. Strategies for microarray analysis of limiting amounts of RNA. Brief Funct 
Genomic Proteomic. 2:31-36. 
Lonsdale-Eccles, J.D., and D.J. Grab. 1987. Purification of African trypanosomes can cause 
biochemical changes in the parasites. The Journal of protozoology. 34:405-408. 
Lucas, R., S. Magez, E. Bajyana Songa, A. Darji, R. Hamers, and P. De Baetselier. 1993. A 
role for TNF-α  during African trypanosomiasis: involvement in parasite control, 
immunosuppression and pathology. Res Immunol. 144:370-376. 
Lumsden, W., C. Kimber, D. Evans, and S. Doig. 1979. Trypanosoma brucei: miniature anion-
exchange centrifugation technique for detection of low parasitaemias: adaptation to 
field use. Trans R Soc Trop Med Hyg. 73:312-317. 
Luo, H., G. Gilinger, D. Mukherjee, and V. Bellofatto. 1999. Transcription initiation at the 
TATA-less spliced leader RNA gene promoter requires at least two DNA-binding 
proteins and a tripartite architecture that includes an initiator element. The Journal of 
biological chemistry. 274:31947-31954. 
Ma, W., M. Wang, Z.-Q. Wang, L. Sun, D. Graber, J. Matthews, R. Champlin, Q. Yi, R.Z. 
Orlowski, L.W. Kwak, D.M. Weber, S.K. Thomas, J. Shah, S. Kornblau, and R.E. 
Davis. 2010. Effect of long-term storage in TRIzol on microarray-based gene 
expression profiling. Cancer epidemiology, biomarkers &amp; prevention : a 
publication of the American Association for Cancer Research, cosponsored by the 
American Society of Preventive Oncology. 19:2445-2452. 
Macaskill, J.A., P.H. Holmes, F.W. Jennings, and G.M. Urquhart. 1981. Immunological 
clearance of 75Se-labelled Trypanosoma brucei in mice. III. Studies in animals with 
acute infections. Immunology. 43:691-698. 
MacLean, L., M. Odiit, D. Okitoi, and J.M. Sternberg. 1999. Plasma nitrate and interferon-
gamma in Trypanosoma brucei rhodesiense infections: evidence that nitric oxide 
production is induced during both early blood-stage and late meningoencephalitic-
stage infections. Transactions of the Royal Society of Tropical Medicine and Hygiene. 
93:169-170. 
MacLean, L., M. Odiit, and J. Sternberg. 2001a. Nitric oxide and cytokine synthesis in human 
African trypanosomiasis. J Infect Dis. 184:1086-1090. 
MacLean, L., M. Odiit, and J.M. Sternberg. 2001b. Nitric oxide and cytokine synthesis in 
human African trypanosomiasis. The Journal of infectious diseases. 184:1086-1090. 
References 
 83 
MacLean, L.M., M. Odiit, J.E. Chisi, P.G.E. Kennedy, and J.M. Sternberg. 2010. Focus-
specific clinical profiles in human African Trypanosomiasis caused by Trypanosoma 
brucei rhodesiense. PLoS neglected tropical diseases. 4:e906. 
Magez, S., G. Caljon, T. TRAN, B. Stijlemans, and M. Radwanska. 2010. Current status of 
vaccination against African trypanosomiasis. Parasitology. 137:2017-2027. 
Magez, S., M. Geuskens, A. Beschin, H. del Favero, H. Verschueren, R. Lucas, E. Pays, and 
P. de Baetselier. 1997. Specific uptake of tumor necrosis factor-α is involved in 
growth control of Trypanosoma brucei. J. Cell. Biol. 137:715-727. 
Magez, S., B. Stijlemans, T. Baral, and P. De Baetselier. 2002. VSG-GPI anchors of African 
trypanosomes: their role in macrophage activation and induction of infection-
associated immunopathology. Microbes and Infection. 4:999-1006. 
Magnus, E., N. Van Meirvenne, T. Vervoort, D. Le Ray, and M. Wery. 1978a. Use of freeze-
dried trypanosomes in the indirect fluorescent antibody test for the serodiagnosis of 
sleeping sickness. Ann Soc Belg Med Trop. 58:103-109. 
Magnus, E., T. Vervoort, and N. Van Meirvenne. 1978b. A card-agglutination test with stained 
trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense 
trypanosomiasis. Ann Soc Belg Med Trop. 58:169-176. 
Malboeuf, C.M., S.J. Isaacs, N.H. Tran, and B. Kim. 2001. Thermal effects on reverse 
transcription: improvement of accuracy and processivity in cDNA synthesis. 
BioTechniques. 30:1074-1078, 1080, 1082, passim. 
Manful, T., A. Fadda, and C. Clayton. 2011. The role of the 5’-3’ exoribonuclease XRNA in 
transcriptome-wide mRNA degradation 
. RNA. 17:2039-2047. 
Manful, T., J. Mulindwa, F.M. Frank, C.E. Clayton, and E. Matovu. 2010. A search for 
Trypanosoma brucei rhodesiense diagnostic antigens by proteomic screening and 
targeted cloning. PloS one. 5:e9630. 
Mansfield, J.M. 1994. T-cell responses to the trypanosome variant surface glycoprotein: a 
new paradigm? Parasitology Today. 10:267-270. 
Mardis, E.R. 2008. Next-generation DNA sequencing methods. Annu Rev Genomics Hum 
Genet. 9:387-402. 
Marioni, J.C., C.E. Mason, S.M. Mane, M. Stephens, and Y. Gilad. 2008. RNA-seq: an 
assessment of technical reproducibility and comparison with gene expression arrays. 
Genome research. 18:1509-1517. 
Marteau, J.-B., S. Mohr, M. Pfister, and S. Visvikis-Siest. 2005. Collection and storage of 
human blood cells for mRNA expression profiling: a 15-month stability study. Clinical 
chemistry. 51:1250-1252. 
Masocha, W., B. Robertson, M.E. Rottenberg, J. Mhlanga, L. Sorokin, and K. Kristensson. 
2004. Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei 
penetration of the blood-brain barrier. J Clin Invest. 114:689-694. 
Mastrokolias, A., J.T. den Dunnen, G.B. van Ommen, P.A.C. &apos;t Hoen, and W.M.C. van 
Roon-Mom. 2012. Increased sensitivity of next generation sequencing-based 
expression profiling after globin reduction in human blood RNA. BMC genomics. 
13:28. 
Metzker, M.L. 2010. Sequencing technologies - the next generation. Nat Rev Genet. 11:31-
46. 
Mikulowska-Mennis, A., T.B. Taylor, P. Vishnu, S.A. Michie, R. Raja, N. Horner, and S.T. 
Kunitake. 2002. High-quality RNA from cells isolated by laser capture 
microdissection. Biotechniques. 33:176-179. 
Mitsuhashi, M., S. Tomozawa, K. Endo, and A. Shinagawa. 2006. Quantification of mRNA in 
whole blood by assessing recovery of RNA and efficiency of cDNA synthesis. Clinical 
chemistry. 52:634-642. 
Mulenga, C., J.D. Mhlanga, K. Kristensson, and B. Robertson. 2001. Trypanosoma brucei 
brucei crosses the blood-brain barrier while tight junction proteins are preserved in a 
rat chronic disease model. Neuropathology and applied neurobiology. 27:77-85. 
Mumba Ngoyi, D., J. Menten, P.P. Pyana, P. Buscher, and V. Lejon. 2013. Stage 
determination in sleeping sickness: comparison of two cell counting and two parasite 
detection techniques. Tropical medicine & international health : TM & IH. 18:778-782. 
Naessens, J., D.M. Mwangi, J. Buza, and S.K. Moloo. 2003. Local skin reaction (chancre) 
induced following inoculation of metacyclic trypanosomes in cattle by tsetse flies is 
dependent on CD4 T lymphocytes. Parasite Immunol. 25:413-419. 
References 
 84 
Namangala, B., P. de Baetselier, L. Brijs, B. Stijlemans, W. Noel, E. Pays, M. Carrington, and 
A. Beschin. 2000. Attenuation of Trypanosoma brucei is associated with reduced 
immunosuppression and concomitant production of Th2 lymphokines. J Infect Dis. 
181:1110-1120. 
Namangala, B., W. Noël, P. De Baetselier, L. Brys, and A. Beschin. 2001. Relative 
contribution of interferon-γ  and interleukin-10 to resistance to murine African 
trypanosomosis. The Journal of infectious diseases. 183:1794-1800. 
Nilsson, D., K. Gunasekera, J. Mani, M. Osteras, L. Farinelli, L. Baerlocher, I. Roditi, and T. 
Ochsenreiter. 2010. Spliced leader trapping reveals widespread alternative splicing 
patterns in the highly dynamic transcriptome of Trypanosoma brucei. PLoS 
pathogens. 6:e1001037. 
Njiru, Z., K. Ndung'u, G. Matete, J. Ndungu, and W. Gibson. 2004. Detection of Trypanosoma 
brucei rhodesiense in animals from sleeping sickness foci in East Africa using the 
serum resistance associated (SRA) gene. Acta Trop. 90:249-254. 
Njiru, Z.K., A.S.J. Mikosza, T. Armstrong, J.C. Enyaru, J.M. Ndung&apos;u, and A.R.C. 
Thompson. 2008. Loop-mediated isothermal amplification (LAMP) method for rapid 
detection of Trypanosoma brucei rhodesiense. PLoS neglected tropical diseases. 
2:e147. 
Njogu, R.M., and J.K. Kiaira. 1982. Trypanosoma brucei: a quick method for separating 
blood-stream trypomastigotes from infected blood by differential osmotic lysis. Comp 
Biochem Physiol A Comp Physiol. 71:265-269. 
Noireau, F., J.P. Gouteux, and J.P. Duteurtre. 1987. Diagnostic value of a card agglutination 
test (Testryp CATT) in the mass screening of human trypanosomiasis in the Congo. 
Bull Soc Pathol Exot Filiales. 80:797-803. 
Odiit, M., F. Kansiime, and J.C. Enyaru. 1997. Duration of symptoms and case fatality of 
sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. 
East Afr Med J. 74:792-795. 
Okomo-Assoumou, M.C., S. Daulouede, J.L. Lemesre, A. N'Zila-Mouanda, and P. 
Vincendeau. 1995. Correlation of high serum levels of tumor necrosis factor-alpha 
with disease severity in human African trypanosomiasis. The American journal of 
tropical medicine and hygiene. 53:539-543. 
Okoniewski, M.J., and C.J. Miller. 2006. Hybridization interactions between probesets in short 
oligo microarrays lead to spurious correlations. BMC Bioinformatics. 2:276. 
Ouellette, M., and B. Papadopoulou. 2009. Coordinated gene expression by post-
transcriptional regulons in African trypanosomes. Journal of biology. 8:100. 
Ovstebo, R., K. Lande, P. Kierulf, and K.B. Haug. 2007. Quantification of relative changes in 
specific mRNAs from frozen whole blood - methodological considerations and clinical 
implications. Clinical chemistry and laboratory medicine : CCLM / FESCC. 45:171-
176. 
Ozsolak, F., and P.M. Milos. 2011. RNA sequencing: advances, challenges and opportunities. 
Nature Publishing Group. 12:87-98. 
Palenchar, J.B., and V. Bellofatto. 2006. Gene transcription in trypanosomes. Molecular and 
biochemical parasitology. 146:135-141. 
Pan, X., R.E. Durrett, H. Zhu, Y. Tanaka, Y. Li, X. Zi, S.L. Marjani, G. Euskirchen, C. Ma, R.H. 
Lamotte, I.-H. Park, M.P. Snyder, C.E. Mason, and S.M. Weissman. 2013. Two 
methods for full-length RNA sequencing for low quantities of cells and single cells. 
Proceedings of the National Academy of Sciences of the United States of America. 
110:594-599. 
Papadopoulos, M.C., P.M. Abel, D. Agranoff, A. Stich, E. Tarelli, B.A. Bell, T. Planche, A. 
Loosemore, S. Saadoun, P. Wilkins, and S. Krishna. 2004. A novel and accurate 
diagnostic test for human African trypanosomiasis. Lancet. 363:1358-1363. 
Pays, E., L. Vanhamme, and D. Perez-Morga. 2004. Antigenic variation in Trypanosoma 
brucei: facts, challenges and mysteries. Current opinion in microbiology. 7:369-374. 
Pays, E., B. Vanhollebeke, L. Vanhamme, F. Paturiaux-Hanocq, D. Nolan, and D. Perez-
Morga. 2006. The trypanolytic factor of human serum. Nat Rev Microbiol. 4:477-486. 
Penchenier, L., P. Grebaut, F. Njokou, V. Eboo Eyenga, and P. Buscher. 2003. Evaluation of 
LATEX/T.b.gambiense for mass screening of Trypanosoma brucei gambiense 
sleeping sickness in Central Africa. Acta Tropica. 85:31-37. 
Penchenier, L., J. Jannin, J.P. Moulia-Pelat, F. Elfassi de la Baume, G. Fadat, B. Chanfreau, 
and P. Eozenou. 1991. Interpretation of the CATT (Card Agglutination 
References 
 85 
Trypanosomiasis Test) in the screening for human trypanosomiasis due to 
Trypanosoma brucei gambiense. Ann Soc Belg Med Trop. 71:221-228. 
Pepin, J., and F. Milord. 1994. The treatment of human African trypanosomiasis. Advances in 
Parasitology. 33:1-47. 
Perez-Novo, C.A., C. Claeys, F. Speleman, P. Van Cauwenberge, C. Bachert, and J. 
Vandesompele. 2005. Impact of RNA quality on reference gene expression stability. 
Biotechniques. 39:52, 54, 56. 
Picozzi, K., E. Fevre, M. Odiit, M. Carrington, M. Eisler, I. Maudlin, and S. Welburn. 2005. 
Sleeping sickness in Uganda: a thin line between two fatal diseases. BMJ. 331:1238-
1241. 
Priotto, G., S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, E. 
Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W. Mutangala, G. Pohlig, C. Schmid, 
U. Karunakara, E. Torreele, and V. Kande. 2009. Nifurtimox-eflornithine combination 
therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a 
multicentre, randomised, phase III, non-inferiority trial. Lancet. 374:56-64. 
Queiroz, R., C. Benz, K. Fellenberg, J.D. Hoheisel, and C. Clayton. 2009. Transcriptome 
analysis of differentiating trypanosomes reveals the existence of multiple post-
transcriptional regulons. BMC genomics. 10:495. 
Radwanska, M., M. Chamekh, L. Vanhamme, F. Claes, S. Magez, E. Magnus, P. de 
Baetselier, P. Buscher, and E. Pays. 2002. The serum resistance-associated gene as 
a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop 
Med Hyg. 67:684-690. 
Rainen, L., U. Oelmueller, S. Jurgensen, R. Wyrich, C. Ballas, J. Schram, C. Herdman, D. 
Bankaitis-Davis, N. Nicholls, D. Trollinger, and V. Tryon. 2002. Stabilization of mRNA 
expression in whole blood samples. Clinical chemistry. 48:1883-1890. 
Raper, J., R. Fung, J. Ghiso, V. Nussenzweig, and S. Tomlinson. 1999. Characterization of a 
novel trypanosome lytic factor from human serum. Infection and immunity. 67:1910-
1916. 
Rapley, R. 1994. Enhancing PCR amplification and sequencing using DNA-binding proteins. 
Mol Biotechnol. 2:295-298. 
Reinitz, D.M., and J.M. Mansfield. 1990. T-cell-independent and T-cell-dependent B-cell 
responses to exposed variant surface glycoprotein epitopes in trypanosome-infected 
mice. Infection and immunity. 58:2337-2342. 
Renger, H.C., and D.R. Wolstenholme. 1971. Kinetoplast and other satellite DNAs of 
kinetoplastic and dyskinetoplastic strains of Trypanosoma. The Journal of cell 
biology. 50:533-540. 
Rhind, S.G., B.H. Sabiston, P.N. Shek, A. Buguet, G. Muanga, A. Stanghellini, M. Dumas, 
and M.W. Radomski. 1997. Effect of melarsoprol treatment on circulating IL-10 and 
TNF-alpha levels in human African trypanosomiasis. Clinical immunology and 
immunopathology. 83:185-189. 
Rifkin, M.R. 1978. Identification of the trypanocidal factor in normal human serum: high 
density lipoprotein. Proceedings of the National Academy of Sciences of the United 
States of America. 75:3450-3454. 
Robays, J., M.M. Bilengue, P. Van der Stuyft, and M. Boelaert. 2004. The effectiveness of 
active population screening and treatment for sleeping sickness control in the 
Democratic Republic of Congo. Tropical medicine & international health : TM & IH. 
9:542-550. 
Roberts, A., C. Trapnell, J. Donaghey, J.L. Rinn, and L. Pachter. 2011. Improving RNA-Seq 
expression estimates by correcting for fragment bias. Genome biology. 12:R22. 
Rodgers, J. 2009. Human African trypanosomiasis, chemotherapy and CNS disease. J 
Neuroimmunol. 211:16-22. 
Rodgers, J., A. Jones, S. Gibaud, B. Bradley, C. McCabe, M.P. Barrett, G. Gettinby, and P.G. 
Kennedy. 2011. Melarsoprol cyclodextrin inclusion complexes as promising oral 
candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis. 
5:e1308. 
Roozemond, R.C. 1976. Ultramicrochemical determination of nucleic acids in individual cells 
using the Zeiss UMSP-I microspectrophotometer. Application to isolated rat 
hepatocytes of different ploidy classes. Histochem J. 8:625-638. 
References 
 86 
Royce, T.E., J.S. Rozowsky, and M.B. Gerstein. 2007. Toward a universal microarray: 
prediction of gene expression through nearest-neighbor probe sequence 
identification. Nucleic Acids Res. 35:99. 
Rutherford, K., J. Parkhill, J. Crook, T. Horsnell, P. Rice, M.A. Rajandream, and B. Barrell. 
2000. Artemis: sequence visualization and annotation. Bioinformatics. 16:944-945. 
Schleifer, K.W., H. Filutowicz, L.R. Schopf, and J.M. Mansfield. 1993. Characterization of T 
helper cell responses to the Trypanosoma variant surface glycoprotein. J Immunol. 
150:2910-2919. 
Shapiro, T.A., and P.T. Englund. 1995. The structure and replication of kinetoplast DNA. 
Annual review of microbiology. 49:117-143. 
Siegel, T.N., K. Gunasekera, G.A.M. Cross, and T. Ochsenreiter. 2011. Gene expression in 
Trypanosoma brucei: lessons from high-throughput RNA sequencing. Trends in 
parasitology. 27:434-441. 
Siegel, T.N., D.R. Hekstra, L.E. Kemp, L.M. Figueiredo, J.E. Lowell, D. Fenyo, X. Wang, S. 
Dewell, and G.A. Cross. 2009. Four histone variants mark the boundaries of 
polycistronic transcription units in Trypanosoma brucei. Genes Dev. 23:1063-1076. 
Siegel, T.N., D.R. Hekstra, X. Wang, S. Dewell, and G.A.M. Cross. 2010. Genome-wide 
analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and 
identification of splicing and polyadenylation sites. Nucleic acids research. 38:4946-
4957. 
Simarro, P., F.J. Louis, and J. Jannin. 2003. Sleeping sickness, forgotten illness: what are the 
consequences in the field? Med Trop (Mars). 63:231-235. 
Simarro, P.P., G. Cecchi, J.R. Franco, M. Paone, A. Diarra, J.A. Ruiz-Postigo, E.M. Fèvre, 
R.C. Mattioli, and J.G. Jannin. 2012a. Estimating and mapping the population at risk 
of sleeping sickness. PLoS neglected tropical diseases. 6:e1859. 
Simarro, P.P., G. Cecchi, M. Paone, and J.R. Franco. 2010. The Atlas of human African 
trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J 
Health …. 
Simarro, P.P., J. Franco, A. Diarra, J.A.R. Postigo, and J. Jannin. 2012b. Update on field use 
of the available drugs for the chemotherapy of human African trypanosomiasis. 
Parasitology. 139:842-846. 
Simarro, P.P., J. Jannin, and P. Cattand. 2008. Eliminating human African trypanosomiasis: 
where do we stand and what comes next? PLoS medicine. 5:e55. 
Simpson, L. 1973. Structure and function of kinetoplast DNA. The Journal of protozoology. 
20:2-8. 
Srivastava, S., and L. Chen. 2010. A two-parameter generalized Poisson model to improve 
the analysis of RNA-seq data. Nucleic acids research. 38:e170. 
Sternberg, J.M. 2004. Human African trypanosomiasis: clinical presentation and immune 
response. Parasite immunology. 26:469-476. 
Stevens, J.R., and S. Brisse. 2004. Systematics of Trypanosomes of medical and Veterinary 
Importance. In The trypanosomiasis. I. Maudlin, P.H. Holmes, and M.A. Miles, 
editors. CABI Wallingford. 1-23. 
Stirewalt, D.L., E.L. Pogosova-Agadjanyan, N. Khalid, D.R. Hare, P.A. Ladne, O. Sala-Torra, 
L.P. Zhao, and J.P. Radich. 2004. Single-stranded linear amplification protocol 
results in reproducible and reliable microarray data from nanogram amounts of 
starting RNA. Genomics. 83:321-331. 
Tachado, D.S., and L. Schofield. 1994. Glycosylphosphatidylinositol toxin of Trypanosoma 
brucei regulates IL-1alpha and TNF-alpha expression in macrophages by protein 
tyrosine kinase mediated signal transduction. Biochem Biophys Res Commun. 
205:984-991. 
Tang, F., C. Barbacioru, E. Nordman, B. Li, N. Xu, V.I. Bashkirov, K. Lao, and M.A. Surani. 
2010. RNA-Seq analysis to capture the transcriptome landscape of a single cell. Nat 
Protoc. 5:516-535. 
Tang, F., C. Barbacioru, Y. Wang, E. Nordman, C. Lee, N. Xu, X. Wang, J. Bodeau, B.B. 
Tuch, A. Siddiqui, K. Lao, and M.A. Surani. 2009. mRNA-Seq whole-transcriptome 
analysis of a single cell. Nature methods. 6:377-382. 
Tang, F., K. Lao, and M.A. Surani. 2011. Development and applications of single-cell 
transcriptome analysis. Nature methods. 8:S6-11. 
Tariq, M.A., H.J. Kim, O. Jejelowo, and N. Pourmand. 2011. Whole-transcriptome RNAseq 
analysis from minute amount of total RNA. Nucleic acids research. 39:e120-e120. 
References 
 87 
Taylor, J.E., and G. Rudenko. 2006. Switching trypanosome coats: what's in the wardrobe? 
Trends Genet. 22:614-620. 
Taylor, K., B. Mertens, V. Lutje, and R. Saya. 1998. Trypanosoma congolense infection of 
trypanotolerant N'Dama (Bos taurus) cattle is associated with decreased secretion of 
nitric oxide by interferon-gamma-activated monocytes and increased transcription of 
interleukin-10. Parasite Immunol. 20:421-429. 
Thach, D.C., B. Lin, E. Walter, R. Kruzelock, R.K. Rowley, C. Tibbetts, and D.A. Stenger. 
2003. Assessment of two methods for handling blood in collection tubes with RNA 
stabilizing agent for surveillance of gene expression profiles with high density 
microarrays. J Immunol Methods. 283:269-279. 
Torreele, E., B. Bourdin Trunz, D. Tweats, M. Kaiser, R. Brun, G. Mazue, M.A. Bray, and B. 
Pecoul. 2010. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical 
development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 4:e923. 
Truc, P., V. Jamonneau, P. N'Guessan, L. N'Dri, P.B. Diallo, and G. Cuny. 1998. 
Trypanosoma brucei ssp. and T congolense: mixed human infection in Cote d'Ivoire. 
Transactions of the Royal Society of Tropical Medicine and Hygiene. 92:537-538. 
Truc, P., V. Lejon, E. Magnus, V. Jamonneau, A. Nangouma, D. Verloo, L. Penchenier, and 
P. Büscher. 2002. Evaluation of the micro-CATT, CATT/Trypanosoma brucei 
gambiense, and LATEX/T. b. gambiense methods for serodiagnosis and surveillance 
of human African trypanosomiasis in West and Central Africa. Bulletin of the World 
Health Organization. 80:882-886. 
UBOS. 2010. Statistical abstract. Uganda bureau of Statistics. 
Uemura, E. 1980. Age-related changes in neuronal RNA content in rhesus monkeys (Macaca 
mulatta). Brain Res Bull. 5:117-119. 
Uzonna, J.E., R.S. Kaushik, J.R. Gordon, and H. Tabel. 1998. Immunoregulation in 
experimental murine Trypanosoma congolense infection: anti-IL-10 antibodies 
reverse trypanosome-mediated suppression of lymphocyte proliferation in vitro and 
moderately prolong the lifespan of genetically susceptible BALB/c mice. Parasite 
Immunol. 20:293-302. 
Uzonna, J.E., R.S. Kaushik, J.R. Gordon, and H. Tabel. 1999. Cytokines and antibody 
responses during Trypanosoma congolense infections in two inbred mouse strains 
that differ in resistance. Parasite Immunol. 21:57-71. 
Uzureau, P., S. Uzureau, L. Lecordier, F. Fontaine, P. Tebabi, F. Homble, A. Grelard, V. 
Zhendre, D.P. Nolan, L. Lins, J.M. Crowet, A. Pays, C. Felu, P. Poelvoorde, B. 
Vanhollebeke, S.K. Moestrup, J. Lyngso, J.S. Pedersen, J.C. Mottram, E.J. Dufourc, 
D. Perez-Morga, and E. Pays. 2013. Mechanism of Trypanosoma brucei gambiense 
resistance to human serum. Nature:430-434. 
Van Gelder, R.N., M.E. von Zastrow, A. Yool, W.C. Dement, J.D. Barchas, and J.H. 
Eberwine. 1990. Amplified RNA synthesized from limited quantities of heterogeneous 
cDNA. Proc Natl Acad Sci U S A. 87:1663-1667. 
Van Meirvenne, N. 1999. Biological diagnosis of human African trypanosomiasis. In Progress 
in Human African Trypanosomiasis, Sleeping Sickness. M. Dumas, B. Bouteille, and 
A. Buguet, editors. Springer–Verlag, Berlin. 273-292. 
Vanhamme, L., and E. Pays. 2004. The trypanosome lytic factor of human serum and the 
molecular basis of sleeping sickness. Int J Parasitol. 34:887-898. 
Vanhamme, L., E. Pays, R. McCulloch, and J.D. Barry. 2001. An update on antigenic 
variation in African trypanosomes. Trends Parasitol. 17:338-343. 
Vanhollebeke, B., and E. Pays. 2010. The trypanolytic factor of human serum: many ways to 
enter 
the parasite, a single way to kill. Mol Microbiol. 76:806–814. 
Veitch, N.J., P.C. Johnson, U. Trivedi, S. Terry, D. Wildridge, and A. Macleod. 2010. Digital 
gene expression analysis of two life cycle stages of the human-infective parasite, 
Trypanosoma brucei gambiense reveals differentially expressed clusters of co-
regulated genes. BMC genomics. 11:124. 
Villalva, C., C. Touriol, P. Seurat, P. Trempat, G. Delsol, and P. Brousset. 2001. Increased 
yield of PCR products by addition of T4 gene 32 protein to the SMART PCR cDNA 
synthesis system. BioTechniques. 31:81-83, 86. 
Vincendeau, P., M.O. Jauberteau-Marchan, S. Dauloue`de, and Z. Ayed. 1999. Immunology 
of African trypanosomiasis. In Progress in human African trypanosomiasis. M. 
Dumas, B. Bouteille, and A. Buguet, editors. Springer-Verlag, Berlin. 137-156. 
References 
 88 
Wang, E. 2005. RNA amplification for successful gene profiling analysis. Journal of 
translational medicine. 3:28. 
Wang, Y., D.E. Prosen, L. Mei, J.C. Sullivan, M. Finney, and P.B. Vander Horn. 2004. A novel 
strategy to engineer DNA polymerases for enhanced processivity and improved 
performance in vitro. Nucleic acids research. 32:1197-1207. 
Wang, Z., M. Gerstein, and M. Snyder. 2009. RNA-Seq: a revolutionary tool for 
transcriptomics. Nature Publishing Group. 10:57-63. 
Welburn, S.C., and M. Odiit. 2002. Recent developments in human African trypanosomiasis. 
Current opinion in infectious diseases. 15:477-484. 
WHO. 1998. Control and surveillance of African trypanosomiasis. Report of a WHO Expert 
Committee. World Health Organization technical report series. 881:I-VI, 1-114. 
WHO. 2012. Research priorities for Chagas disease, human African trypanosomiasis and 
leishmaniasis. World Health Organization technical report series:v-xii, 1-100. 
Woo, P.T. 1970. The haematocrit centrifuge technique for the diagnosis of African 
trypanosomiasis. Acta Tropica. 27:384-386. 
Xiang, C.C., M. Chen, L. Ma, Q.N. Phan, J.M. Inman, O.A. Kozhich, and M.J. Brownstein. 
2003. A new strategy to amplify degraded RNA from small tissue samples for 
microarray studies. Nucleic acids research. 31:e53. 
Xong, H.V., L. Vanhamme, M. Chamekh, C.E. Chimfwembe, J. Van Den Abbeele, A. Pays, N. 
Van Meirvenne, R. Hamers, P. De Baetselier, and E. Pays. 1998. A VSG expression 
site-associated gene confers resistance to human serum in Trypanosoma 
rhodesiense. Cell. 95:839-846. 
 
  89 
List of Figures 
Figure 1.1 Map showing the spatial distribution of Human African Trypanosomiasis on African 
continent. 
Figure 1.2 Schematic representation of the T. brucei genome 
Figure 2.1 Representation of the counting chamber of the Neubauer hemocytometer 
Figure 3.1 Schematic representation of the trypanosome RNA amplification and sequencing 
workflow. 
Figure 3.2 Second strand synthesis of double stranded cDNA in the Trypanosome HeLa mix. 
Figure 3.3 Amplification of double stranded cDNA in the Trypanosome HeLa mix. 
Figure 3.4 Schematic representation of unamplified Trypanosome RNA library preparation for 
RNASeq.  
Figure 3.5 Artemis visualization of read coverage over entire chromosome. 
Figure 3.6 Scatter plots comparing the transcriptome libraries of the trypanosome amplified 
(TH) and unamplified (T) replicates. 
Figure 3.7 Scatter plots comparing the HiSeq2000 transcriptome libraries of the trypanosome 
amplified (TH), unamplified (T) and polyA+ BF1313. 
Figure 3.8 Scatter plot analysis of the effect of transcript length on the relative gene 
expression. 
Figure 3.9 Analysis of gene length and gene position bias in the amplified, unamplified and 
polyA+ BF1313 transcriptome libraries. 
Figure 3.10 Gene expression analysis of four transcripts (Tb927.1.2330, Tb927.4.4220, 
Tb927.8.5260, Tb927.10.8710) based on length and abundance. 
Figure 3.11 Study sample collection from Sleeping sickness patients. 
Figure 3.12 Dot plot and column graph showing the cell counts in the samples collected from 
patients. 
Figure 3.13 Analysis of RNA extracted from the patient samples. 
Figure 3.14 Agilent bioanalyzer traces of the amplified trypanosome transcriptomes from the 
patient samples. 
Figure 3.15 Effect of purification on the transcriptome of Trypanosomes. 
Figure 3.16 Scatter plots relating the percentage relative standard deviation to the mean 
RPKM of each gene (single dot). 
Figure 3.17 Gene expression analysis between purified and un-purified trypanosomes. 
Figure 3.18 Relative effect of purification methods on transcriptome of Trypanosomes. 
Figure 3.19 Alignment of genomic reads to the T. brucei 927 reference genome. 
Figure 3.20 Gene copy number variation in T. brucei strains. 
  
  90 
List of Tables 
Table 2.1 Trypanosome culture HMI-9 medium 
Table 2.2 Oligo-dT cellulose pretreatment protocol 
Table 2.3 8% Urea-acrylamide gel preparation mix 
Table 2.4 List of reverse primers for qRT-PCR 
Table 3.1 Summary of sequenced read output and mapping to the T. brucei TREU 927 
reference genome 
Table 3.2 Summary of cell count data from the 23 patients recruited for the study 
Table 3.3 Comparison of the expected and observed total RNA amounts from the patient 
buffy coat and CSF samples.  
Table 3.3 Summary of sequenced 100bp paired end reads from genomes from Trypanosome 
strains. 
 
